1
|
Luen SJ, Viale G, Nik-Zainal S, Savas P, Kammler R, Dell'Orto P, Biasi O, Degasperi A, Brown LC, Láng I, MacGrogan G, Tondini C, Bellet M, Villa F, Bernardo A, Ciruelos E, Karlsson P, Neven P, Climent M, Müller B, Jochum W, Bonnefoi H, Martino S, Davidson NE, Geyer C, Chia SK, Ingle JN, Coleman R, Solbach C, Thürlimann B, Colleoni M, Coates AS, Goldhirsch A, Fleming GF, Francis PA, Speed TP, Regan MM, Loi S. Genomic characterisation of hormone receptor-positive breast cancer arising in very young women. Ann Oncol 2023; 34:397-409. [PMID: 36709040 PMCID: PMC10619213 DOI: 10.1016/j.annonc.2023.01.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2022] [Revised: 12/14/2022] [Accepted: 01/15/2023] [Indexed: 01/26/2023] Open
Abstract
BACKGROUND Very young premenopausal women diagnosed with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+HER2-) early breast cancer (EBC) have higher rates of recurrence and death for reasons that remain largely unexplained. PATIENTS AND METHODS Genomic sequencing was applied to HR+HER2- tumours from patients enrolled in the Suppression of Ovarian Function Trial (SOFT) to determine genomic drivers that are enriched in young premenopausal women. Genomic alterations were characterised using next-generation sequencing from a subset of 1276 patients (deep targeted sequencing, n = 1258; whole-exome sequencing in a young-age, case-control subsample, n = 82). We defined copy number (CN) subgroups and assessed for features suggestive of homologous recombination deficiency (HRD). Genomic alteration frequencies were compared between young premenopausal women (<40 years) and older premenopausal women (≥40 years), and assessed for associations with distant recurrence-free interval (DRFI) and overall survival (OS). RESULTS Younger women (<40 years, n = 359) compared with older women (≥40 years, n = 917) had significantly higher frequencies of mutations in GATA3 (19% versus 16%) and CN amplifications (CNAs) (47% versus 26%), but significantly lower frequencies of mutations in PIK3CA (32% versus 47%), CDH1 (3% versus 9%), and MAP3K1 (7% versus 12%). Additionally, they had significantly higher frequencies of features suggestive of HRD (27% versus 21%) and a higher proportion of PIK3CA mutations with concurrent CNAs (23% versus 11%). Genomic features suggestive of HRD, PIK3CA mutations with CNAs, and CNAs were associated with significantly worse DRFI and OS compared with those without these features. These poor prognostic features were enriched in younger patients: present in 72% of patients aged <35 years, 54% aged 35-39 years, and 40% aged ≥40 years. Poor prognostic features [n = 584 (46%)] versus none [n = 692 (54%)] had an 8-year DRFI of 84% versus 94% and OS of 88% versus 96%. Younger women (<40 years) had the poorest outcomes: 8-year DRFI 74% versus 85% and OS 80% versus 93%, respectively. CONCLUSION These results provide insights into genomic alterations that are enriched in young women with HR+HER2- EBC, provide rationale for genomic subgrouping, and highlight priority molecular targets for future clinical trials.
Collapse
Affiliation(s)
- S J Luen
- Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia
| | - G Viale
- International Breast Cancer Study Group Central Pathology Office, IEO European Institute of Oncology IRCCS, University of Milan, Milan, Italy
| | - S Nik-Zainal
- Department of Medical Genetics & MRC Cancer Unit, The Clinical School, University of Cambridge, Cambridge, UK
| | - P Savas
- Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia
| | - R Kammler
- International Breast Cancer Study Group, Coordinating Center, Central Pathology Office, Bern, Switzerland
| | - P Dell'Orto
- International Breast Cancer Study Group Central Pathology Office, Department of Pathology, IEO European Institute of Oncology IRCCS, Milan, Italy
| | - O Biasi
- Division of Pathology and Laboratory Medicine, IEO European Institute of Oncology IRCCS, Milan, Italy
| | - A Degasperi
- Department of Medical Genetics & MRC Cancer Unit, The Clinical School, University of Cambridge, Cambridge, UK
| | - L C Brown
- Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia
| | - I Láng
- Istenhegyi Health Center Oncology Clinic, National Institute of Oncology, Budapest, Hungary
| | - G MacGrogan
- Biopathology Department, Institut Bergonié Comprehensive Cancer Centre, Bordeaux, France
| | - C Tondini
- Osp. Papa Giovanni XXIII, Bergamo, Italy
| | - M Bellet
- Vall d'Hebron Institute of Oncology (VHIO) and Vall d'Hebron University Hospital, Barcelona, Spain
| | - F Villa
- Oncology Unit, Department of Oncology, Alessandro Manzoni Hospital, ASST Lecco, Lecco, Italy
| | - A Bernardo
- ICS Maugeri IRCCS, Medical Oncology Unit of Pavia Institute, Italy
| | - E Ciruelos
- University Hospital 12 de Octubre, Madrid, Spain
| | - P Karlsson
- Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - P Neven
- Gynecologic Oncology and Multidisciplinary Breast Center, University Hospitals UZ-Leuven, KU Leuven, Leuven, Belgium
| | - M Climent
- Instituto Valenciano de Oncologia, Valencia, Spain
| | - B Müller
- Chilean Cooperative Group for Oncologic Research (GOCCHI), Santiago, Chile
| | - W Jochum
- Institute of Pathology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland; Swiss Group for Clinical Cancer Research (SAKK), Berne, Switzerland
| | - H Bonnefoi
- Institut Bergonié Comprehensive Cancer Centre, Université de Bordeaux, INSERM U1218, Bordeaux, France; European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium
| | - S Martino
- The Angeles Clinic and Research Institute, Santa Monica, USA
| | - N E Davidson
- Fred Hutchinson Cancer Research Center, University of Washington, Seattle, USA
| | - C Geyer
- Houston Methodist Cancer Center, NRG Oncology, Houston, USA
| | - S K Chia
- BC Cancer and Canadian Cancer Trials Group, Vancouver, Canada
| | - J N Ingle
- Mayo Clinic, Rochester, Minnesota, USA
| | - R Coleman
- National Institute for Health Research (NIHR) Cancer Research Network, University of Sheffield, Sheffield, UK
| | - C Solbach
- Breast Center, University Hospital, Goethe University Frankfurt, Frankfurt, Germany
| | - B Thürlimann
- Swiss Group for Clinical Cancer Research (SAKK), Berne, Switzerland; Breast Center, Kantonsspital, St. Gallen, Switzerland
| | - M Colleoni
- Division of Medical Senology, IEO, European Institute of Oncology IRCCS, Milan, Italy
| | - A S Coates
- International Breast Cancer Study Group and University of Sydney, Sydney, Australia
| | - A Goldhirsch
- International Breast Cancer Study Group (IBCSG), Bern Switzerland and IEO European Institute of Oncology IRCCS, Milan, Italy
| | - G F Fleming
- Section of Hematology Oncology, The University of Chicago, Chicago, USA
| | - P A Francis
- Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia
| | - T P Speed
- Bioinformatics Division, Walter and Eliza Hall Institute, Melbourne, Australia
| | - M M Regan
- Division of Biostatistics, International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
| | - S Loi
- Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia.
| |
Collapse
|
2
|
Leao I, Zamora E, Gomez Pardo P, Arumi de Dios M, Pimentel I, Escriva de Romani S, Ortiz Velez C, Cruellas Lapena M, Sanz L, Borrell M, Vega Cano K, Gómez-Puerto D, De La Torre J, Espinosa-Bravo M, Oliveira M, Fasani R, Nuciforo P, Saura C, Peg V, Bellet M. 87P EPClin vs OncotypeDx in invasive lobular cancer (ILC). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.03.102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
3
|
Peg V, de los Ángeles N, Vieites B, Bellet M, Castilla C, Gomez Pardo P, Pérez-Luque A, Lopez M, Salvador Bofill F, Alfaro L, Perez Garcia J, Espinosa-Bravo M. 102P Long-term prediction of clinical outcomes by the 21-gene test in HR+ HER2- breast cancer patients with residual disease after neoadjuvant chemotherapy. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.03.118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
4
|
Bellet M, Stincardini C, Pariano M, Renga G, D’Onofrio F, Santarelli I, Costantini C, Romani L. 389: Circadian rhythm and cystic fibrosis: Diurnal regulation of the host response to pulmonary infections in CF. J Cyst Fibros 2021. [DOI: 10.1016/s1569-1993(21)01813-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
5
|
Costantini C, Pariano M, Pampalone G, Zelante T, Macchioni L, Galarini R, Costanzi E, Bellet M, Giovagnoli S, Saba J, Cellini B, Romani L. 521: Dual targeting of host and fungal sphingosine-1-phosphate lyase as antifungal strategy in cystic fibrosis. J Cyst Fibros 2021. [DOI: 10.1016/s1569-1993(21)01945-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
6
|
Danaietash P, Verweij P, Wang J, Dresser G, Kantola I, Lawrence MK, Narkiewicz K, Schlaich M, Bellet M. Investigating the endothelin receptor antagonist aprocitentan in resistant hypertension: design and baseline characteristics of the PRECISION study. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.2362] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
The endothelin (ET) system plays an important role in hypertension, especially in volume and salt-dependent forms, which are common in patients with resistant hypertension (RHT). Therapies targeting the ET system may provide a new treatment option. A Phase 2 dose-finding study demonstrated an effect of the dual ET receptor antagonist aprocitentan monotherapy on blood pressure (BP) [1].
PRECISION is a randomized, parallel-group, Phase 3 study assessing the short-term effect of 2 doses of aprocitentan (12.5 mg and 25 mg) and its long-term sustained effect on BP. Following randomization, patients entered a 4-week, double-blind (DB), placebo-controlled part, followed by aprocitentan 25 mg for 32 weeks, and a 12-week, placebo-controlled, randomized withdrawal part (Figure 1). The primary endpoint is the change in systolic BP (SBP) from randomization to week 4 and the key secondary endpoint is the change in SBP from re-randomization to week 40.
The study enrolled 1971 patients with RHT diagnosed according to the site's medical practice, from 193 centres worldwide. Entry criteria included sitting SBP [SiSBP] ≥140 mmHg, measured by unattended automated office BP (uAOBP, reducing the white coat effect), despite the use of ≥3 antihypertensive medications. During the screening period of 4 to 12 weeks, secondary causes of hypertension were excluded by the investigator and patients still having SiSBP ≥140 mmHg were switched from their individual antihypertensive drugs to a single-tablet, triple combination of valsartan 160 mg /amlodipine 5 or 10 mg /hydrochlorothiazide 25 mg o.d. (minimizing medical inertia and improving drug adherence) for at least 4 weeks before entering the placebo run-in (RI) period. The screening failure rate of 53% is indicative of the high incidence of apparent RHT within the hypertensive population.
Patients continuing having SiSBP ≥140 mmHg on triple therapy (true RHT) then entered the 4-week, single-blind placebo RI period. Of these patients, 20% failed to be randomized, most frequently because of SiSBP <140 mmHg, possibly due to a placebo effect.
As of 12 March 2021, 860 patients were in the placebo RI period and 664 patients were randomized, 30% from North America, 62% from Europe, and 8% from Asia/Australia. Mean age was 61.8 years (standard deviation [SD]=10.8). 40% of patients were women, 11% were Black, 5% Asian, and 83% White. Mean body mass index (BMI) was 33.6 kg/m2 (SD=6.4) and mean estimated glomerular filtration rate (eGFR) was 76.8 mL/min/1.73 m2 (including 21% chronic kidney disease [CKD] stage 3–4 patients). Medical history included diabetes (54%), myocardial infarction (30%), stroke (23%), congestive heart failure (19%), and sleep apnoea (15%). In addition to the standardized antihypertensive medication, 59% of patients used beta-blockers. Mean baseline SiSBP/SiDBP was 153/88 mmHg. Results of the trial will be available in 2022.
Funding Acknowledgement
Type of funding sources: Private company. Main funding source(s): The PRECISION study is sponsored by Idorsia Pharmaceuticals Ltd.
Collapse
Affiliation(s)
- P Danaietash
- Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland
| | - P Verweij
- Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland
| | - J Wang
- Department of Hypertension, The Shanghai Institute of Hypertension, Ruijin Hospital, Jiaotong University School of Medicine, Shanghai, China
| | - G Dresser
- London Health Sciences Centre – Victoria Hospital, London, Ontario, Canada
| | - I Kantola
- Turku University Hospital, Division of Medicine, Turku, Finland
| | - M K Lawrence
- Carteret Medical Group, Morehead City, North Carolina, United States of America
| | - K Narkiewicz
- Department of Hypertension and Diabetology, Medical University of Gdansk, Gdansk, Poland
| | - M Schlaich
- Dobney Hypertension Centre, School of Medicine - Royal Perth Hospital Unit/RPH Research Foundation, Faculty of Medicine, Dentistry & Health Sciences, The University of Western Australia, Perth, Western Australia, Australia
| | - M Bellet
- Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland
| |
Collapse
|
7
|
Saoudi Gonzalez N, Papakonstantinou A, Pimentel I, Suñol A, Bellet M, Zamora E, Ortiz C, Saura Manich C, Villacampa Javierre G, Antunes De Melo e Oliveira A. 152P Meta-analysis of the prognostic value of circulating tumor DNA (ctDNA) in patients (pts) with early breast cancer (EBC). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.433] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
8
|
Brasó-Maristany F, Palafox M, Monserrat L, Bellet M, Oliveira M, Capelán M, Galván P, Martínez D, Chic N, Viaplana C, Dienstmann R, Nuciforo P, Saura Manich C, Prat A, Serra V. 16P Understanding the biologic determinants of ribociclib efficacy in breast cancer. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.03.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
9
|
Bellet M, Morales Murillo S, Gasol Cudos A, Amillano K, Chic N, González-Farré X, Villagrasa P, Ferrero-Cafiero J, Pascual T, Prat A, Lange C, Saura Manich C. 40TiP SOLTI-1802 ONAWA trial: A window of opportunity trial of onapristone (ONA) in postmenopausal women with estrogen and progesterone receptor-positive/HER2-negative (ER+/PgR+/HER2-) early breast cancer (EBC). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.03.054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
10
|
Danaietash P, Verweij P, Flamion B, Menard J, Bellet M. 34Efficacy and safety of various doses of the new dual endothelin receptor antagonist aprocitentan in the treatment of hypertension. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz747.0004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Endothelin Receptor Antagonists (ERAs) have been investigated for the treatment of a variety of cardiovascular conditions because of their potent vasodilating properties. However, until now, ERAs have only been registered for the treatment of pulmonary arterial hypertension and scleroderma-induced digital ulcers. This class of drugs may also be useful in the treatment of difficult to control hypertension with a medical need.
Purpose
To investigate the efficacy and safety of various doses of the new dual ERA, aprocitentan, in the treatment of hypertension in order to determine the most appropriate dose(s) for further clinical development using an unattended, automated office BP (AOBP) device (BpTRU). This Phase 2 trial was registered at ClinicalTrials.gov [NCT02603809].
Methods
Eligible patients with hypertension (mean sitting systolic/diastolic BP 149.7/97.6 mmHg) received aprocitentan 5, 10, 25 or 50 mg, matching placebo or lisinopril 20 mg as a positive control, once daily for 8 weeks using a randomised, double-blind, parallel-group study design. AOBP was assessed at baseline and weeks 2, 4, 8, and 10 (withdrawal) by recording multiple BP readings with the patient resting quietly. Additionally, 24 h ambulatory BP monitoring was performed at baseline and week 8.
Results
A total of 490 eligible patients were randomised to the double-blind phase with 430 subjects successfully completing 8 weeks of treatment. Decreases in sitting systolic/diastolic AOBP, from baseline to week 8 were 10.3/6.3, 15.0/9.9, 18.5/12.0 and 15.1/10.0 mmHg for aprocitentan 5, 10, 25, and 50 mg, respectively vs. 7.7/4.9 mmHg for placebo and 12.8/8.4 mmHg for lisinopril. No changes in heart rate or body weight were observed for any dose of aprocitentan.
Modelling the dose-response suggested that the maximal effect of aprocitentan is achieved at a dose of approximately 25 mg and that 70% of this effect is already observed at a dose of 10 mg. Aprocitentan treatment was associated with decreases in haemoglobin, haematocrit, and albumin which exhibited a monotonic dose-response relationship, in line with its known vasodilating effects. Estimated increases in plasma volume were 3.0%, 5.1%, 6.9%, and 9.5% for aprocitentan 5, 10, 25, and 50 mg, respectively, vs. 1.6% for lisinopril and a decrease of 0.3% for placebo. All these values are below the accepted pathophysiological threshold of 10%.
The overall incidence of adverse events observed in the aprocitentan groups (ranging from 22.0% to 40.2%) was similar to that seen in the placebo group (36.6%). Overall, the most common events were hypertension, headache, and nasopharyngitis.
Conclusions
These findings support the use of aprocitentan at doses between 10 and 25 mg for further investigation as a potential treatment for hypertension.
Acknowledgement/Funding
Actelion conducted study. Drug discovery & early clinical pipeline demerged during Johnson & Johnson acquisition. Idorsia supported abstract.
Collapse
Affiliation(s)
- P Danaietash
- Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland
| | - P Verweij
- Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland
| | - B Flamion
- Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland
| | - J Menard
- University Paris-Descartes, Paris, France
| | - M Bellet
- Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland
| |
Collapse
|
11
|
Buckland G, Travier N, Arribas L, Del Barco S, Pernas S, Zamora E, Bellet M, Cirauqui B, Margelí M, Muñoz M, Tusquets I, Arcusa A, Javierre C, Moreno F, Valverde Y, Jansen E, Chajès V, Castro C, Agudo A. Changes in dietary intake, plasma carotenoids and erythrocyte membrane fatty acids in breast cancer survivors after a lifestyle intervention: results from a single-arm trial. J Hum Nutr Diet 2019; 32:468-479. [PMID: 30663156 DOI: 10.1111/jhn.12621] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
BACKGROUND The influence of nutrition on breast cancer prognosis is still inconclusive and therefore dietary interventions incorporating dietary biomarkers are needed to confirm compliance with dietary goals and clarify biological mechanisms. The present study assessed whether a lifestyle intervention in breast cancer survivors could affect dietary biomarkers of fruit and vegetables and fatty acids. METHODS In this phase II single-arm trial, 37 overweight/obese early stage breast cancer patients completed a 12-week diet and exercise intervention. The intervention involved 1-h weekly diet sessions delivered by a dietician and 75-min bi-weekly physical activity sessions of moderate-to-high intensity led by trained monitors. Before and after the intervention, three 24-h dietary recalls were carried out to calculate nutrient intakes and, in addition, blood samples were taken to measure plasma carotenoids, vitamin E and retinol concentrations and erythrocyte membrane fatty acid (EFA) composition. Wilcoxon signed rank tests were used to assess changes in dietary and biomarkers measurements over the intervention period. RESULTS After the intervention, there was a significant increase in the intake of dietary carotenoids (+15.1% compared to baseline) but not plasma carotenoids levels (+6.3%). Regarding the EFA levels, we observed a significant decrease in percentage of saturated fatty acids (-1.4%) and n-6 polyunsaturated fatty acids (-2.9%) and an increase in monounsaturated fatty acids (1.7%) and total and long-chain n-3 polyunsaturated fatty acids (by 13.1% and 13.7%, respectively). A favourable decrease in the ratio of long-chain n-6 to n-3 polyunsaturated fatty acids (-9.1%) was also observed. CONCLUSIONS After a short-term diet and exercise intervention in overweight/obese breast cancer survivors, we observed significant changes in dietary nutrients and fatty acid biomarkers, suggesting positive dietary changes that could be relevant for breast cancer prognosis.
Collapse
Affiliation(s)
- G Buckland
- Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain
| | - N Travier
- Unit Breast Cancer Screening Unit, Cancer Prevention and Control Program, Catalan Institute of Oncology-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain
| | - L Arribas
- Clinical Nutrition Unit, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain
| | - S Del Barco
- Department of Medical Oncology-ICO, Hospital Universitari de Girona Dr Josep Trueta, Girona, Spain
| | - S Pernas
- Breast Cancer Unit, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain
| | - E Zamora
- Department of Breast Cancer Oncology, Hospital Universitari Vall d'Hebron, Barcelona, Spain
| | - M Bellet
- Department of Breast Cancer Oncology, Hospital Universitari Vall d'Hebron, Barcelona, Spain
| | - B Cirauqui
- Department of Medical Oncology-ICO, Hospital Germans Trias i Pujol, Badalona, Spain
| | - M Margelí
- Department of Medical Oncology-ICO, Hospital Germans Trias i Pujol, Badalona, Spain
| | - M Muñoz
- Translational Genomics and Targeted Therapeutics, Institut d'Investigacions Biomèdiques Pi i Sunyer IDIBAPS, Barcelona, Spain
| | - I Tusquets
- Department of Medical Oncology, Hospital del Mar, Barcelona, Spain
| | - A Arcusa
- Department of Medical Oncology, Consorci Sanitari de Terrassa, Terrassa, Spain
| | - C Javierre
- Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Spain
| | - F Moreno
- Breast Cancer Unit, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain
| | - Y Valverde
- Breast Cancer Unit, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain
| | - E Jansen
- Centre for Health Protection, National Institute for Public Health and the Environment, Bilthoven, The Netherlands
| | - V Chajès
- Nutrition and Metabolism Department, International Agency for Research on Cancer, Lyon, France
| | - C Castro
- Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain
| | - A Agudo
- Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain
| |
Collapse
|
12
|
Cortes J, Calvo V, Ramírez-Merino N, O'Shaughnessy J, Brufsky A, Robert N, Vidal M, Muñoz E, Perez J, Dawood S, Saura C, Di Cosimo S, González-Martín A, Bellet M, Silva OE, Miles D, Llombart A, Baselga J. Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. Ann Oncol 2019; 30:1179. [PMID: 30624662 DOI: 10.1093/annonc/mdy535] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/09/2023] Open
|
13
|
Serrano C, Cortés J, De Mattos-Arruda L, Bellet M, Gómez P, Saura C, Pérez J, Vidal M, Muñoz-Couselo E, Carreras MJ, Sánchez-Ollé G, Tabernero J, Baselga J, Di Cosimo S. Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann Oncol 2019; 30:1178. [PMID: 30624599 DOI: 10.1093/annonc/mdy534] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
14
|
Salvador J, Ciruelos EM, Prat A, Jiménez-Rodríguez B, de la Cruz L, Martínez N, Villanueva Vázquez R, de Toro R, Antón A, Moreno F, Alvarez I, Gavila J, Quiroga V, Vicente E, de la Haba J, González-Santiago S, Díaz N, Barnadas A, Cantos Sánchez de Ibargüen B, Delgado JI, Bellet M, Gimeno A, Sanz S, Martin M. Abstract P6-18-17: Ribociclib + letrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC) with no prior endocrine therapy (ET) for ABC: CompLEEment-1 trial, preliminary results from Spanish population. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-18-17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The phase III Monaleesa-2, Monaleesa-3 and Monaleesa-7 trials have shown significantly improved PFS for the combination ribociclib + ET vs ET + placebo in pre-, peri-, and postmenopausal women with HR+/HER2–, first and second line aBC. The Compleement-1 trial is a phase IIIb, single-arm, open-label, international study to assess the safety and efficacy of ribociclib + letrozole in men and women who have not received prior ET for HR+, HER2– ABC [J Clin Oncol 36, 2018 (suppl; abstr 1056)].
Methods: 526 patients with HR+, HER2– ABC, ≤1 line of prior CT, and no prior ET for aBC were enrolled in the Compleement-1trial in Spain from April 2017 to January 2018. Patients received ribociclib (600 mg/day, 3 weeks on/1 week off) + letrozole (2.5 mg/day); men and premenopausal women received concomitant goserelin (3.6 mg subcutaneous implant every 28 days). The primary objective was safety and tolerability. Here we report on a sub-analysis from the Spanish population of Compleement-1 trial including baseline characteristics and early safety results for the first patients enrolled who completed at least 56 days of follow-up or discontinued before the cut-off date (3rd Oct 2017).
Results: One hundred fifty four patients constituted the analytical cohort for this sub-analysis. Demographics and baseline characteristics: median age was 52 years (range 24-82); 1% of patients were male, 31.8% female pre-menopausal and 67.5% female post-menopausal; 44.2% vs 38.3% of patients had visceral disease vs bone only disease; 49.9% patients had ≥2 metastatic sites; and 34.4% of patients presented as de novo stage IV. The median exposure for study treatment was 1.8 months (range 0.8-1.8). The grade 3/4 events reported >1% included neutropenia (50%), increased GGT levels (3.2%), leukopenia (1.3%), and increased ALT (1.3%). QTcF prolongation >480ms based on ECG data was reported in 1.2% patients. Median dose intensity for ribociclib was 600mg/day (range 476.5-600); 11% of patients required one dose reduction (8.4% due to AEs), 59.7% had at least one dose interruption (57.1% due to AEs) and 9.7% were permanently discontinued (4.5% due to AEs).
Conclusions: Preliminary safety results from this Compleement-1 sub-analysis including Spanish population are consistent with previous data presented from Monaleesa-2, Monaleesa-3, Monaleesa-7 and Compleement-1. These data support the predictable and manageable safety profile of ribociclib in combination with letrozole. Clinical trial information: NCT02941926
Citation Format: Salvador J, Ciruelos EM, Prat A, Jiménez-Rodríguez B, de la Cruz L, Martínez N, Villanueva Vázquez R, de Toro R, Antón A, Moreno F, Alvarez I, Gavila J, Quiroga V, Vicente E, de la Haba J, González-Santiago S, Díaz N, Barnadas A, Cantos Sánchez de Ibargüen B, Delgado JI, Bellet M, Gimeno A, Sanz S, Martin M. Ribociclib + letrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC) with no prior endocrine therapy (ET) for ABC: CompLEEment-1 trial, preliminary results from Spanish population [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-18-17.
Collapse
Affiliation(s)
- J Salvador
- Virgen del Rocio University Hospital. Biomedicine Institute (IBIS), Sevilla, Andalucia, Spain; University Hospital 12 de Octubre, Madrid, Spain; Clinic Barcelona University Hospital, Barcelona, Cataluña, Spain; Virgen de la Victoria University Hospital, Malaga, Andalucia, Spain; Virgen de la Macarena University Hospital, Sevilla, Andalucia, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Institut Català d'Oncologia-Hospital Duran i Reynals, Barcelona, Cataluña, Spain; Jerez University Hospital, Jerez, Andalucia, Spain; Miguel Servet University Hospital, Zaragoza, Aragon, Spain; Hospital Clínico San Carlos, Madrid, Spain; Donostia University Hospital, Donostia, Pais Vasco, Spain; Fundación Instituto Valenciano de Oncologia, Valencia, Spain; Catalan Institut of Oncology (ICO) - Hospital Germans Trias i Pujol, Badalona, Cataluña, Spain; Insular Gran Canaria University Hospital, Gran Canaria, Canarias, Spain; Reina Sofia University Hospital, Cordoba, Andalucia, Spain; San Pedro de Alcantara University H
| | - EM Ciruelos
- Virgen del Rocio University Hospital. Biomedicine Institute (IBIS), Sevilla, Andalucia, Spain; University Hospital 12 de Octubre, Madrid, Spain; Clinic Barcelona University Hospital, Barcelona, Cataluña, Spain; Virgen de la Victoria University Hospital, Malaga, Andalucia, Spain; Virgen de la Macarena University Hospital, Sevilla, Andalucia, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Institut Català d'Oncologia-Hospital Duran i Reynals, Barcelona, Cataluña, Spain; Jerez University Hospital, Jerez, Andalucia, Spain; Miguel Servet University Hospital, Zaragoza, Aragon, Spain; Hospital Clínico San Carlos, Madrid, Spain; Donostia University Hospital, Donostia, Pais Vasco, Spain; Fundación Instituto Valenciano de Oncologia, Valencia, Spain; Catalan Institut of Oncology (ICO) - Hospital Germans Trias i Pujol, Badalona, Cataluña, Spain; Insular Gran Canaria University Hospital, Gran Canaria, Canarias, Spain; Reina Sofia University Hospital, Cordoba, Andalucia, Spain; San Pedro de Alcantara University H
| | - A Prat
- Virgen del Rocio University Hospital. Biomedicine Institute (IBIS), Sevilla, Andalucia, Spain; University Hospital 12 de Octubre, Madrid, Spain; Clinic Barcelona University Hospital, Barcelona, Cataluña, Spain; Virgen de la Victoria University Hospital, Malaga, Andalucia, Spain; Virgen de la Macarena University Hospital, Sevilla, Andalucia, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Institut Català d'Oncologia-Hospital Duran i Reynals, Barcelona, Cataluña, Spain; Jerez University Hospital, Jerez, Andalucia, Spain; Miguel Servet University Hospital, Zaragoza, Aragon, Spain; Hospital Clínico San Carlos, Madrid, Spain; Donostia University Hospital, Donostia, Pais Vasco, Spain; Fundación Instituto Valenciano de Oncologia, Valencia, Spain; Catalan Institut of Oncology (ICO) - Hospital Germans Trias i Pujol, Badalona, Cataluña, Spain; Insular Gran Canaria University Hospital, Gran Canaria, Canarias, Spain; Reina Sofia University Hospital, Cordoba, Andalucia, Spain; San Pedro de Alcantara University H
| | - B Jiménez-Rodríguez
- Virgen del Rocio University Hospital. Biomedicine Institute (IBIS), Sevilla, Andalucia, Spain; University Hospital 12 de Octubre, Madrid, Spain; Clinic Barcelona University Hospital, Barcelona, Cataluña, Spain; Virgen de la Victoria University Hospital, Malaga, Andalucia, Spain; Virgen de la Macarena University Hospital, Sevilla, Andalucia, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Institut Català d'Oncologia-Hospital Duran i Reynals, Barcelona, Cataluña, Spain; Jerez University Hospital, Jerez, Andalucia, Spain; Miguel Servet University Hospital, Zaragoza, Aragon, Spain; Hospital Clínico San Carlos, Madrid, Spain; Donostia University Hospital, Donostia, Pais Vasco, Spain; Fundación Instituto Valenciano de Oncologia, Valencia, Spain; Catalan Institut of Oncology (ICO) - Hospital Germans Trias i Pujol, Badalona, Cataluña, Spain; Insular Gran Canaria University Hospital, Gran Canaria, Canarias, Spain; Reina Sofia University Hospital, Cordoba, Andalucia, Spain; San Pedro de Alcantara University H
| | - L de la Cruz
- Virgen del Rocio University Hospital. Biomedicine Institute (IBIS), Sevilla, Andalucia, Spain; University Hospital 12 de Octubre, Madrid, Spain; Clinic Barcelona University Hospital, Barcelona, Cataluña, Spain; Virgen de la Victoria University Hospital, Malaga, Andalucia, Spain; Virgen de la Macarena University Hospital, Sevilla, Andalucia, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Institut Català d'Oncologia-Hospital Duran i Reynals, Barcelona, Cataluña, Spain; Jerez University Hospital, Jerez, Andalucia, Spain; Miguel Servet University Hospital, Zaragoza, Aragon, Spain; Hospital Clínico San Carlos, Madrid, Spain; Donostia University Hospital, Donostia, Pais Vasco, Spain; Fundación Instituto Valenciano de Oncologia, Valencia, Spain; Catalan Institut of Oncology (ICO) - Hospital Germans Trias i Pujol, Badalona, Cataluña, Spain; Insular Gran Canaria University Hospital, Gran Canaria, Canarias, Spain; Reina Sofia University Hospital, Cordoba, Andalucia, Spain; San Pedro de Alcantara University H
| | - N Martínez
- Virgen del Rocio University Hospital. Biomedicine Institute (IBIS), Sevilla, Andalucia, Spain; University Hospital 12 de Octubre, Madrid, Spain; Clinic Barcelona University Hospital, Barcelona, Cataluña, Spain; Virgen de la Victoria University Hospital, Malaga, Andalucia, Spain; Virgen de la Macarena University Hospital, Sevilla, Andalucia, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Institut Català d'Oncologia-Hospital Duran i Reynals, Barcelona, Cataluña, Spain; Jerez University Hospital, Jerez, Andalucia, Spain; Miguel Servet University Hospital, Zaragoza, Aragon, Spain; Hospital Clínico San Carlos, Madrid, Spain; Donostia University Hospital, Donostia, Pais Vasco, Spain; Fundación Instituto Valenciano de Oncologia, Valencia, Spain; Catalan Institut of Oncology (ICO) - Hospital Germans Trias i Pujol, Badalona, Cataluña, Spain; Insular Gran Canaria University Hospital, Gran Canaria, Canarias, Spain; Reina Sofia University Hospital, Cordoba, Andalucia, Spain; San Pedro de Alcantara University H
| | - R Villanueva Vázquez
- Virgen del Rocio University Hospital. Biomedicine Institute (IBIS), Sevilla, Andalucia, Spain; University Hospital 12 de Octubre, Madrid, Spain; Clinic Barcelona University Hospital, Barcelona, Cataluña, Spain; Virgen de la Victoria University Hospital, Malaga, Andalucia, Spain; Virgen de la Macarena University Hospital, Sevilla, Andalucia, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Institut Català d'Oncologia-Hospital Duran i Reynals, Barcelona, Cataluña, Spain; Jerez University Hospital, Jerez, Andalucia, Spain; Miguel Servet University Hospital, Zaragoza, Aragon, Spain; Hospital Clínico San Carlos, Madrid, Spain; Donostia University Hospital, Donostia, Pais Vasco, Spain; Fundación Instituto Valenciano de Oncologia, Valencia, Spain; Catalan Institut of Oncology (ICO) - Hospital Germans Trias i Pujol, Badalona, Cataluña, Spain; Insular Gran Canaria University Hospital, Gran Canaria, Canarias, Spain; Reina Sofia University Hospital, Cordoba, Andalucia, Spain; San Pedro de Alcantara University H
| | - R de Toro
- Virgen del Rocio University Hospital. Biomedicine Institute (IBIS), Sevilla, Andalucia, Spain; University Hospital 12 de Octubre, Madrid, Spain; Clinic Barcelona University Hospital, Barcelona, Cataluña, Spain; Virgen de la Victoria University Hospital, Malaga, Andalucia, Spain; Virgen de la Macarena University Hospital, Sevilla, Andalucia, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Institut Català d'Oncologia-Hospital Duran i Reynals, Barcelona, Cataluña, Spain; Jerez University Hospital, Jerez, Andalucia, Spain; Miguel Servet University Hospital, Zaragoza, Aragon, Spain; Hospital Clínico San Carlos, Madrid, Spain; Donostia University Hospital, Donostia, Pais Vasco, Spain; Fundación Instituto Valenciano de Oncologia, Valencia, Spain; Catalan Institut of Oncology (ICO) - Hospital Germans Trias i Pujol, Badalona, Cataluña, Spain; Insular Gran Canaria University Hospital, Gran Canaria, Canarias, Spain; Reina Sofia University Hospital, Cordoba, Andalucia, Spain; San Pedro de Alcantara University H
| | - A Antón
- Virgen del Rocio University Hospital. Biomedicine Institute (IBIS), Sevilla, Andalucia, Spain; University Hospital 12 de Octubre, Madrid, Spain; Clinic Barcelona University Hospital, Barcelona, Cataluña, Spain; Virgen de la Victoria University Hospital, Malaga, Andalucia, Spain; Virgen de la Macarena University Hospital, Sevilla, Andalucia, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Institut Català d'Oncologia-Hospital Duran i Reynals, Barcelona, Cataluña, Spain; Jerez University Hospital, Jerez, Andalucia, Spain; Miguel Servet University Hospital, Zaragoza, Aragon, Spain; Hospital Clínico San Carlos, Madrid, Spain; Donostia University Hospital, Donostia, Pais Vasco, Spain; Fundación Instituto Valenciano de Oncologia, Valencia, Spain; Catalan Institut of Oncology (ICO) - Hospital Germans Trias i Pujol, Badalona, Cataluña, Spain; Insular Gran Canaria University Hospital, Gran Canaria, Canarias, Spain; Reina Sofia University Hospital, Cordoba, Andalucia, Spain; San Pedro de Alcantara University H
| | - F Moreno
- Virgen del Rocio University Hospital. Biomedicine Institute (IBIS), Sevilla, Andalucia, Spain; University Hospital 12 de Octubre, Madrid, Spain; Clinic Barcelona University Hospital, Barcelona, Cataluña, Spain; Virgen de la Victoria University Hospital, Malaga, Andalucia, Spain; Virgen de la Macarena University Hospital, Sevilla, Andalucia, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Institut Català d'Oncologia-Hospital Duran i Reynals, Barcelona, Cataluña, Spain; Jerez University Hospital, Jerez, Andalucia, Spain; Miguel Servet University Hospital, Zaragoza, Aragon, Spain; Hospital Clínico San Carlos, Madrid, Spain; Donostia University Hospital, Donostia, Pais Vasco, Spain; Fundación Instituto Valenciano de Oncologia, Valencia, Spain; Catalan Institut of Oncology (ICO) - Hospital Germans Trias i Pujol, Badalona, Cataluña, Spain; Insular Gran Canaria University Hospital, Gran Canaria, Canarias, Spain; Reina Sofia University Hospital, Cordoba, Andalucia, Spain; San Pedro de Alcantara University H
| | - I Alvarez
- Virgen del Rocio University Hospital. Biomedicine Institute (IBIS), Sevilla, Andalucia, Spain; University Hospital 12 de Octubre, Madrid, Spain; Clinic Barcelona University Hospital, Barcelona, Cataluña, Spain; Virgen de la Victoria University Hospital, Malaga, Andalucia, Spain; Virgen de la Macarena University Hospital, Sevilla, Andalucia, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Institut Català d'Oncologia-Hospital Duran i Reynals, Barcelona, Cataluña, Spain; Jerez University Hospital, Jerez, Andalucia, Spain; Miguel Servet University Hospital, Zaragoza, Aragon, Spain; Hospital Clínico San Carlos, Madrid, Spain; Donostia University Hospital, Donostia, Pais Vasco, Spain; Fundación Instituto Valenciano de Oncologia, Valencia, Spain; Catalan Institut of Oncology (ICO) - Hospital Germans Trias i Pujol, Badalona, Cataluña, Spain; Insular Gran Canaria University Hospital, Gran Canaria, Canarias, Spain; Reina Sofia University Hospital, Cordoba, Andalucia, Spain; San Pedro de Alcantara University H
| | - J Gavila
- Virgen del Rocio University Hospital. Biomedicine Institute (IBIS), Sevilla, Andalucia, Spain; University Hospital 12 de Octubre, Madrid, Spain; Clinic Barcelona University Hospital, Barcelona, Cataluña, Spain; Virgen de la Victoria University Hospital, Malaga, Andalucia, Spain; Virgen de la Macarena University Hospital, Sevilla, Andalucia, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Institut Català d'Oncologia-Hospital Duran i Reynals, Barcelona, Cataluña, Spain; Jerez University Hospital, Jerez, Andalucia, Spain; Miguel Servet University Hospital, Zaragoza, Aragon, Spain; Hospital Clínico San Carlos, Madrid, Spain; Donostia University Hospital, Donostia, Pais Vasco, Spain; Fundación Instituto Valenciano de Oncologia, Valencia, Spain; Catalan Institut of Oncology (ICO) - Hospital Germans Trias i Pujol, Badalona, Cataluña, Spain; Insular Gran Canaria University Hospital, Gran Canaria, Canarias, Spain; Reina Sofia University Hospital, Cordoba, Andalucia, Spain; San Pedro de Alcantara University H
| | - V Quiroga
- Virgen del Rocio University Hospital. Biomedicine Institute (IBIS), Sevilla, Andalucia, Spain; University Hospital 12 de Octubre, Madrid, Spain; Clinic Barcelona University Hospital, Barcelona, Cataluña, Spain; Virgen de la Victoria University Hospital, Malaga, Andalucia, Spain; Virgen de la Macarena University Hospital, Sevilla, Andalucia, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Institut Català d'Oncologia-Hospital Duran i Reynals, Barcelona, Cataluña, Spain; Jerez University Hospital, Jerez, Andalucia, Spain; Miguel Servet University Hospital, Zaragoza, Aragon, Spain; Hospital Clínico San Carlos, Madrid, Spain; Donostia University Hospital, Donostia, Pais Vasco, Spain; Fundación Instituto Valenciano de Oncologia, Valencia, Spain; Catalan Institut of Oncology (ICO) - Hospital Germans Trias i Pujol, Badalona, Cataluña, Spain; Insular Gran Canaria University Hospital, Gran Canaria, Canarias, Spain; Reina Sofia University Hospital, Cordoba, Andalucia, Spain; San Pedro de Alcantara University H
| | - E Vicente
- Virgen del Rocio University Hospital. Biomedicine Institute (IBIS), Sevilla, Andalucia, Spain; University Hospital 12 de Octubre, Madrid, Spain; Clinic Barcelona University Hospital, Barcelona, Cataluña, Spain; Virgen de la Victoria University Hospital, Malaga, Andalucia, Spain; Virgen de la Macarena University Hospital, Sevilla, Andalucia, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Institut Català d'Oncologia-Hospital Duran i Reynals, Barcelona, Cataluña, Spain; Jerez University Hospital, Jerez, Andalucia, Spain; Miguel Servet University Hospital, Zaragoza, Aragon, Spain; Hospital Clínico San Carlos, Madrid, Spain; Donostia University Hospital, Donostia, Pais Vasco, Spain; Fundación Instituto Valenciano de Oncologia, Valencia, Spain; Catalan Institut of Oncology (ICO) - Hospital Germans Trias i Pujol, Badalona, Cataluña, Spain; Insular Gran Canaria University Hospital, Gran Canaria, Canarias, Spain; Reina Sofia University Hospital, Cordoba, Andalucia, Spain; San Pedro de Alcantara University H
| | - J de la Haba
- Virgen del Rocio University Hospital. Biomedicine Institute (IBIS), Sevilla, Andalucia, Spain; University Hospital 12 de Octubre, Madrid, Spain; Clinic Barcelona University Hospital, Barcelona, Cataluña, Spain; Virgen de la Victoria University Hospital, Malaga, Andalucia, Spain; Virgen de la Macarena University Hospital, Sevilla, Andalucia, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Institut Català d'Oncologia-Hospital Duran i Reynals, Barcelona, Cataluña, Spain; Jerez University Hospital, Jerez, Andalucia, Spain; Miguel Servet University Hospital, Zaragoza, Aragon, Spain; Hospital Clínico San Carlos, Madrid, Spain; Donostia University Hospital, Donostia, Pais Vasco, Spain; Fundación Instituto Valenciano de Oncologia, Valencia, Spain; Catalan Institut of Oncology (ICO) - Hospital Germans Trias i Pujol, Badalona, Cataluña, Spain; Insular Gran Canaria University Hospital, Gran Canaria, Canarias, Spain; Reina Sofia University Hospital, Cordoba, Andalucia, Spain; San Pedro de Alcantara University H
| | - S González-Santiago
- Virgen del Rocio University Hospital. Biomedicine Institute (IBIS), Sevilla, Andalucia, Spain; University Hospital 12 de Octubre, Madrid, Spain; Clinic Barcelona University Hospital, Barcelona, Cataluña, Spain; Virgen de la Victoria University Hospital, Malaga, Andalucia, Spain; Virgen de la Macarena University Hospital, Sevilla, Andalucia, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Institut Català d'Oncologia-Hospital Duran i Reynals, Barcelona, Cataluña, Spain; Jerez University Hospital, Jerez, Andalucia, Spain; Miguel Servet University Hospital, Zaragoza, Aragon, Spain; Hospital Clínico San Carlos, Madrid, Spain; Donostia University Hospital, Donostia, Pais Vasco, Spain; Fundación Instituto Valenciano de Oncologia, Valencia, Spain; Catalan Institut of Oncology (ICO) - Hospital Germans Trias i Pujol, Badalona, Cataluña, Spain; Insular Gran Canaria University Hospital, Gran Canaria, Canarias, Spain; Reina Sofia University Hospital, Cordoba, Andalucia, Spain; San Pedro de Alcantara University H
| | - N Díaz
- Virgen del Rocio University Hospital. Biomedicine Institute (IBIS), Sevilla, Andalucia, Spain; University Hospital 12 de Octubre, Madrid, Spain; Clinic Barcelona University Hospital, Barcelona, Cataluña, Spain; Virgen de la Victoria University Hospital, Malaga, Andalucia, Spain; Virgen de la Macarena University Hospital, Sevilla, Andalucia, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Institut Català d'Oncologia-Hospital Duran i Reynals, Barcelona, Cataluña, Spain; Jerez University Hospital, Jerez, Andalucia, Spain; Miguel Servet University Hospital, Zaragoza, Aragon, Spain; Hospital Clínico San Carlos, Madrid, Spain; Donostia University Hospital, Donostia, Pais Vasco, Spain; Fundación Instituto Valenciano de Oncologia, Valencia, Spain; Catalan Institut of Oncology (ICO) - Hospital Germans Trias i Pujol, Badalona, Cataluña, Spain; Insular Gran Canaria University Hospital, Gran Canaria, Canarias, Spain; Reina Sofia University Hospital, Cordoba, Andalucia, Spain; San Pedro de Alcantara University H
| | - A Barnadas
- Virgen del Rocio University Hospital. Biomedicine Institute (IBIS), Sevilla, Andalucia, Spain; University Hospital 12 de Octubre, Madrid, Spain; Clinic Barcelona University Hospital, Barcelona, Cataluña, Spain; Virgen de la Victoria University Hospital, Malaga, Andalucia, Spain; Virgen de la Macarena University Hospital, Sevilla, Andalucia, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Institut Català d'Oncologia-Hospital Duran i Reynals, Barcelona, Cataluña, Spain; Jerez University Hospital, Jerez, Andalucia, Spain; Miguel Servet University Hospital, Zaragoza, Aragon, Spain; Hospital Clínico San Carlos, Madrid, Spain; Donostia University Hospital, Donostia, Pais Vasco, Spain; Fundación Instituto Valenciano de Oncologia, Valencia, Spain; Catalan Institut of Oncology (ICO) - Hospital Germans Trias i Pujol, Badalona, Cataluña, Spain; Insular Gran Canaria University Hospital, Gran Canaria, Canarias, Spain; Reina Sofia University Hospital, Cordoba, Andalucia, Spain; San Pedro de Alcantara University H
| | - B Cantos Sánchez de Ibargüen
- Virgen del Rocio University Hospital. Biomedicine Institute (IBIS), Sevilla, Andalucia, Spain; University Hospital 12 de Octubre, Madrid, Spain; Clinic Barcelona University Hospital, Barcelona, Cataluña, Spain; Virgen de la Victoria University Hospital, Malaga, Andalucia, Spain; Virgen de la Macarena University Hospital, Sevilla, Andalucia, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Institut Català d'Oncologia-Hospital Duran i Reynals, Barcelona, Cataluña, Spain; Jerez University Hospital, Jerez, Andalucia, Spain; Miguel Servet University Hospital, Zaragoza, Aragon, Spain; Hospital Clínico San Carlos, Madrid, Spain; Donostia University Hospital, Donostia, Pais Vasco, Spain; Fundación Instituto Valenciano de Oncologia, Valencia, Spain; Catalan Institut of Oncology (ICO) - Hospital Germans Trias i Pujol, Badalona, Cataluña, Spain; Insular Gran Canaria University Hospital, Gran Canaria, Canarias, Spain; Reina Sofia University Hospital, Cordoba, Andalucia, Spain; San Pedro de Alcantara University H
| | - JI Delgado
- Virgen del Rocio University Hospital. Biomedicine Institute (IBIS), Sevilla, Andalucia, Spain; University Hospital 12 de Octubre, Madrid, Spain; Clinic Barcelona University Hospital, Barcelona, Cataluña, Spain; Virgen de la Victoria University Hospital, Malaga, Andalucia, Spain; Virgen de la Macarena University Hospital, Sevilla, Andalucia, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Institut Català d'Oncologia-Hospital Duran i Reynals, Barcelona, Cataluña, Spain; Jerez University Hospital, Jerez, Andalucia, Spain; Miguel Servet University Hospital, Zaragoza, Aragon, Spain; Hospital Clínico San Carlos, Madrid, Spain; Donostia University Hospital, Donostia, Pais Vasco, Spain; Fundación Instituto Valenciano de Oncologia, Valencia, Spain; Catalan Institut of Oncology (ICO) - Hospital Germans Trias i Pujol, Badalona, Cataluña, Spain; Insular Gran Canaria University Hospital, Gran Canaria, Canarias, Spain; Reina Sofia University Hospital, Cordoba, Andalucia, Spain; San Pedro de Alcantara University H
| | - M Bellet
- Virgen del Rocio University Hospital. Biomedicine Institute (IBIS), Sevilla, Andalucia, Spain; University Hospital 12 de Octubre, Madrid, Spain; Clinic Barcelona University Hospital, Barcelona, Cataluña, Spain; Virgen de la Victoria University Hospital, Malaga, Andalucia, Spain; Virgen de la Macarena University Hospital, Sevilla, Andalucia, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Institut Català d'Oncologia-Hospital Duran i Reynals, Barcelona, Cataluña, Spain; Jerez University Hospital, Jerez, Andalucia, Spain; Miguel Servet University Hospital, Zaragoza, Aragon, Spain; Hospital Clínico San Carlos, Madrid, Spain; Donostia University Hospital, Donostia, Pais Vasco, Spain; Fundación Instituto Valenciano de Oncologia, Valencia, Spain; Catalan Institut of Oncology (ICO) - Hospital Germans Trias i Pujol, Badalona, Cataluña, Spain; Insular Gran Canaria University Hospital, Gran Canaria, Canarias, Spain; Reina Sofia University Hospital, Cordoba, Andalucia, Spain; San Pedro de Alcantara University H
| | - A Gimeno
- Virgen del Rocio University Hospital. Biomedicine Institute (IBIS), Sevilla, Andalucia, Spain; University Hospital 12 de Octubre, Madrid, Spain; Clinic Barcelona University Hospital, Barcelona, Cataluña, Spain; Virgen de la Victoria University Hospital, Malaga, Andalucia, Spain; Virgen de la Macarena University Hospital, Sevilla, Andalucia, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Institut Català d'Oncologia-Hospital Duran i Reynals, Barcelona, Cataluña, Spain; Jerez University Hospital, Jerez, Andalucia, Spain; Miguel Servet University Hospital, Zaragoza, Aragon, Spain; Hospital Clínico San Carlos, Madrid, Spain; Donostia University Hospital, Donostia, Pais Vasco, Spain; Fundación Instituto Valenciano de Oncologia, Valencia, Spain; Catalan Institut of Oncology (ICO) - Hospital Germans Trias i Pujol, Badalona, Cataluña, Spain; Insular Gran Canaria University Hospital, Gran Canaria, Canarias, Spain; Reina Sofia University Hospital, Cordoba, Andalucia, Spain; San Pedro de Alcantara University H
| | - S Sanz
- Virgen del Rocio University Hospital. Biomedicine Institute (IBIS), Sevilla, Andalucia, Spain; University Hospital 12 de Octubre, Madrid, Spain; Clinic Barcelona University Hospital, Barcelona, Cataluña, Spain; Virgen de la Victoria University Hospital, Malaga, Andalucia, Spain; Virgen de la Macarena University Hospital, Sevilla, Andalucia, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Institut Català d'Oncologia-Hospital Duran i Reynals, Barcelona, Cataluña, Spain; Jerez University Hospital, Jerez, Andalucia, Spain; Miguel Servet University Hospital, Zaragoza, Aragon, Spain; Hospital Clínico San Carlos, Madrid, Spain; Donostia University Hospital, Donostia, Pais Vasco, Spain; Fundación Instituto Valenciano de Oncologia, Valencia, Spain; Catalan Institut of Oncology (ICO) - Hospital Germans Trias i Pujol, Badalona, Cataluña, Spain; Insular Gran Canaria University Hospital, Gran Canaria, Canarias, Spain; Reina Sofia University Hospital, Cordoba, Andalucia, Spain; San Pedro de Alcantara University H
| | - M Martin
- Virgen del Rocio University Hospital. Biomedicine Institute (IBIS), Sevilla, Andalucia, Spain; University Hospital 12 de Octubre, Madrid, Spain; Clinic Barcelona University Hospital, Barcelona, Cataluña, Spain; Virgen de la Victoria University Hospital, Malaga, Andalucia, Spain; Virgen de la Macarena University Hospital, Sevilla, Andalucia, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Institut Català d'Oncologia-Hospital Duran i Reynals, Barcelona, Cataluña, Spain; Jerez University Hospital, Jerez, Andalucia, Spain; Miguel Servet University Hospital, Zaragoza, Aragon, Spain; Hospital Clínico San Carlos, Madrid, Spain; Donostia University Hospital, Donostia, Pais Vasco, Spain; Fundación Instituto Valenciano de Oncologia, Valencia, Spain; Catalan Institut of Oncology (ICO) - Hospital Germans Trias i Pujol, Badalona, Cataluña, Spain; Insular Gran Canaria University Hospital, Gran Canaria, Canarias, Spain; Reina Sofia University Hospital, Cordoba, Andalucia, Spain; San Pedro de Alcantara University H
| |
Collapse
|
15
|
Spoerke JM, Daemen A, Chang CW, Giltnane J, Metcalfe C, Dickler MN, Bardia A, Perez Fidalgo JA, Mayer IA, Boni V, Winer EP, Hamilton EP, Bellet M, Urruticoechea A, Gonzalez Martin A, Cortes J, Martin M, Gates M, Cheeti S, Fredrickson J, Wang X, Friedman LS, Liu L, Li R, Chan IT, Mueller L, Milan S, Lauchle J, Humke EW, Lackner MR. Abstract P5-11-01: Phamacodynamic and circulating tumor DNA evaluation in a phase I study of GDC-0927, a selective estrogen receptor antagonist/ degrader (SERD). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p5-11-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Modulation of estrogen activity and/or synthesis is the mainstay therapeutic strategy in the treatment of ER positive breast cancer. However, despite the effectiveness of available endocrine therapies, many patients ultimately relapse or develop resistance to these agents via estrogen-dependent and estrogen-independent mechanisms, including mutations in ESR1 affecting the ER ligand binding domain that drive ER-dependent transcription and proliferation in the absence of estrogen. Based on preclinical and clinical data, SERDs are expected be effective in patients harboring ESR1 mutations. Biomarker analysis was performed on plasma and tumor samples from the Phase I study of GDC-0927 in metastatic breast cancer (Dickler et al, SABCS 2017) with the goal of evaluating activity in both ESR1 mutant and wildtype tumors, and to assess ER pathway modulation.
Methods: Hotspot mutations in ESR1, PIK3CA, and AKT1 were analyzed in baseline, on-treatment and end of treatment plasma derived circulating tumor DNA (ctDNA) using the BEAMing assay in patients treated at multiple dose levels of GDC-0927. A subset of samples was analyzed with Foundation Medicine's next generation sequencing ctDNA assay (FACT), which covers genomic alterations in 62 commonly altered genes. Paired pre- and on-treatment biopsies were collected to assess ER pathway modulation. ER, PR, and Ki67 protein levels were analyzed by immunohistochemistry. Gene expression analysis was performed using Illumina's RNA Access library preparation kit followed by paired-end (2x50b, 50M reads) sequencing on the HiSeq.
Results: Baseline and on-treatment plasma samples were available for 40 patients. ESR1 and PIK3CA mutations were observed in 52% and 33% of patient baseline samples, respectively (BEAMing method). Mutant allele frequencies (MAF) generally declined in the first on-treatment samples collected for both ESR1 (16 out of 21 samples) and PIK3CA (7 out of 12 samples). The majority of the reductions were greater than 95% relative to baseline. Increases in ESR1 MAFs were observed in later time-points and were not associated with any particular ESR1 mutation. There were six instances for which an ESR1 mutation was detected in an on-treatment sample that was not detected in the baseline sample, three at L536P and one each at D538G, L536H, and S463P, and four out of six with MAFs close to the limit of detection. The FACT assay also detected alterations in CDH1, NF1, PTEN, and TP53 in baseline samples. The relationship between MAF changes and clinical benefit to GDC-0927 will be presented. A predefined, experimentally-derived set of ER target genes were evaluated in pre- and on-treatment tumor biopsy pairs from six patients. Four of the six patients showed evidence of suppression in ER pathway activity, one patient treated at the 1000 mg dose level and three at the 1400 mg dose. The degree of pathway suppression was associated with pre-treatment pathway levels and decreases of ER and Ki67 protein levels.
Conclusions: We report here evidence of consistent reduction of ESR1 and PIK3CA ctDNA in patients treated with GDC-0927. ER pathway suppression was observed at both the transcript and protein level confirming pharmacodynamic activity of the SERD.
Citation Format: Spoerke JM, Daemen A, Chang C-W, Giltnane J, Metcalfe C, Dickler MN, Bardia A, Perez Fidalgo JA, Mayer IA, Boni V, Winer EP, Hamilton EP, Bellet M, Urruticoechea A, Gonzalez Martin A, Cortes J, Martin M, Gates M, Cheeti S, Fredrickson J, Wang X, Friedman LS, Liu L, Li R, Chan IT, Mueller L, Milan S, Lauchle J, Humke EW, Lackner MR. Phamacodynamic and circulating tumor DNA evaluation in a phase I study of GDC-0927, a selective estrogen receptor antagonist/ degrader (SERD) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-11-01.
Collapse
Affiliation(s)
- JM Spoerke
- Genentech, Inc., South San Francisco, CA; Eli Lilly, Indianapolis, IN; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Hospital Clinico Universitario de Valencia, INCLIVA, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; START Madrid-CIOCC, Hm Hospital Sanchinarro, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute / Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Ideaya Biosciences, South San Francisco, CA
| | - A Daemen
- Genentech, Inc., South San Francisco, CA; Eli Lilly, Indianapolis, IN; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Hospital Clinico Universitario de Valencia, INCLIVA, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; START Madrid-CIOCC, Hm Hospital Sanchinarro, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute / Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Ideaya Biosciences, South San Francisco, CA
| | - C-W Chang
- Genentech, Inc., South San Francisco, CA; Eli Lilly, Indianapolis, IN; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Hospital Clinico Universitario de Valencia, INCLIVA, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; START Madrid-CIOCC, Hm Hospital Sanchinarro, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute / Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Ideaya Biosciences, South San Francisco, CA
| | - J Giltnane
- Genentech, Inc., South San Francisco, CA; Eli Lilly, Indianapolis, IN; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Hospital Clinico Universitario de Valencia, INCLIVA, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; START Madrid-CIOCC, Hm Hospital Sanchinarro, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute / Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Ideaya Biosciences, South San Francisco, CA
| | - C Metcalfe
- Genentech, Inc., South San Francisco, CA; Eli Lilly, Indianapolis, IN; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Hospital Clinico Universitario de Valencia, INCLIVA, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; START Madrid-CIOCC, Hm Hospital Sanchinarro, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute / Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Ideaya Biosciences, South San Francisco, CA
| | - MN Dickler
- Genentech, Inc., South San Francisco, CA; Eli Lilly, Indianapolis, IN; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Hospital Clinico Universitario de Valencia, INCLIVA, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; START Madrid-CIOCC, Hm Hospital Sanchinarro, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute / Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Ideaya Biosciences, South San Francisco, CA
| | - A Bardia
- Genentech, Inc., South San Francisco, CA; Eli Lilly, Indianapolis, IN; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Hospital Clinico Universitario de Valencia, INCLIVA, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; START Madrid-CIOCC, Hm Hospital Sanchinarro, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute / Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Ideaya Biosciences, South San Francisco, CA
| | - JA Perez Fidalgo
- Genentech, Inc., South San Francisco, CA; Eli Lilly, Indianapolis, IN; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Hospital Clinico Universitario de Valencia, INCLIVA, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; START Madrid-CIOCC, Hm Hospital Sanchinarro, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute / Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Ideaya Biosciences, South San Francisco, CA
| | - IA Mayer
- Genentech, Inc., South San Francisco, CA; Eli Lilly, Indianapolis, IN; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Hospital Clinico Universitario de Valencia, INCLIVA, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; START Madrid-CIOCC, Hm Hospital Sanchinarro, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute / Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Ideaya Biosciences, South San Francisco, CA
| | - V Boni
- Genentech, Inc., South San Francisco, CA; Eli Lilly, Indianapolis, IN; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Hospital Clinico Universitario de Valencia, INCLIVA, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; START Madrid-CIOCC, Hm Hospital Sanchinarro, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute / Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Ideaya Biosciences, South San Francisco, CA
| | - EP Winer
- Genentech, Inc., South San Francisco, CA; Eli Lilly, Indianapolis, IN; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Hospital Clinico Universitario de Valencia, INCLIVA, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; START Madrid-CIOCC, Hm Hospital Sanchinarro, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute / Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Ideaya Biosciences, South San Francisco, CA
| | - EP Hamilton
- Genentech, Inc., South San Francisco, CA; Eli Lilly, Indianapolis, IN; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Hospital Clinico Universitario de Valencia, INCLIVA, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; START Madrid-CIOCC, Hm Hospital Sanchinarro, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute / Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Ideaya Biosciences, South San Francisco, CA
| | - M Bellet
- Genentech, Inc., South San Francisco, CA; Eli Lilly, Indianapolis, IN; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Hospital Clinico Universitario de Valencia, INCLIVA, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; START Madrid-CIOCC, Hm Hospital Sanchinarro, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute / Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Ideaya Biosciences, South San Francisco, CA
| | - A Urruticoechea
- Genentech, Inc., South San Francisco, CA; Eli Lilly, Indianapolis, IN; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Hospital Clinico Universitario de Valencia, INCLIVA, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; START Madrid-CIOCC, Hm Hospital Sanchinarro, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute / Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Ideaya Biosciences, South San Francisco, CA
| | - A Gonzalez Martin
- Genentech, Inc., South San Francisco, CA; Eli Lilly, Indianapolis, IN; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Hospital Clinico Universitario de Valencia, INCLIVA, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; START Madrid-CIOCC, Hm Hospital Sanchinarro, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute / Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Ideaya Biosciences, South San Francisco, CA
| | - J Cortes
- Genentech, Inc., South San Francisco, CA; Eli Lilly, Indianapolis, IN; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Hospital Clinico Universitario de Valencia, INCLIVA, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; START Madrid-CIOCC, Hm Hospital Sanchinarro, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute / Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Ideaya Biosciences, South San Francisco, CA
| | - M Martin
- Genentech, Inc., South San Francisco, CA; Eli Lilly, Indianapolis, IN; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Hospital Clinico Universitario de Valencia, INCLIVA, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; START Madrid-CIOCC, Hm Hospital Sanchinarro, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute / Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Ideaya Biosciences, South San Francisco, CA
| | - M Gates
- Genentech, Inc., South San Francisco, CA; Eli Lilly, Indianapolis, IN; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Hospital Clinico Universitario de Valencia, INCLIVA, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; START Madrid-CIOCC, Hm Hospital Sanchinarro, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute / Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Ideaya Biosciences, South San Francisco, CA
| | - S Cheeti
- Genentech, Inc., South San Francisco, CA; Eli Lilly, Indianapolis, IN; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Hospital Clinico Universitario de Valencia, INCLIVA, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; START Madrid-CIOCC, Hm Hospital Sanchinarro, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute / Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Ideaya Biosciences, South San Francisco, CA
| | - J Fredrickson
- Genentech, Inc., South San Francisco, CA; Eli Lilly, Indianapolis, IN; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Hospital Clinico Universitario de Valencia, INCLIVA, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; START Madrid-CIOCC, Hm Hospital Sanchinarro, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute / Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Ideaya Biosciences, South San Francisco, CA
| | - X Wang
- Genentech, Inc., South San Francisco, CA; Eli Lilly, Indianapolis, IN; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Hospital Clinico Universitario de Valencia, INCLIVA, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; START Madrid-CIOCC, Hm Hospital Sanchinarro, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute / Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Ideaya Biosciences, South San Francisco, CA
| | - LS Friedman
- Genentech, Inc., South San Francisco, CA; Eli Lilly, Indianapolis, IN; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Hospital Clinico Universitario de Valencia, INCLIVA, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; START Madrid-CIOCC, Hm Hospital Sanchinarro, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute / Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Ideaya Biosciences, South San Francisco, CA
| | - L Liu
- Genentech, Inc., South San Francisco, CA; Eli Lilly, Indianapolis, IN; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Hospital Clinico Universitario de Valencia, INCLIVA, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; START Madrid-CIOCC, Hm Hospital Sanchinarro, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute / Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Ideaya Biosciences, South San Francisco, CA
| | - R Li
- Genentech, Inc., South San Francisco, CA; Eli Lilly, Indianapolis, IN; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Hospital Clinico Universitario de Valencia, INCLIVA, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; START Madrid-CIOCC, Hm Hospital Sanchinarro, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute / Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Ideaya Biosciences, South San Francisco, CA
| | - IT Chan
- Genentech, Inc., South San Francisco, CA; Eli Lilly, Indianapolis, IN; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Hospital Clinico Universitario de Valencia, INCLIVA, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; START Madrid-CIOCC, Hm Hospital Sanchinarro, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute / Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Ideaya Biosciences, South San Francisco, CA
| | - L Mueller
- Genentech, Inc., South San Francisco, CA; Eli Lilly, Indianapolis, IN; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Hospital Clinico Universitario de Valencia, INCLIVA, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; START Madrid-CIOCC, Hm Hospital Sanchinarro, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute / Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Ideaya Biosciences, South San Francisco, CA
| | - S Milan
- Genentech, Inc., South San Francisco, CA; Eli Lilly, Indianapolis, IN; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Hospital Clinico Universitario de Valencia, INCLIVA, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; START Madrid-CIOCC, Hm Hospital Sanchinarro, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute / Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Ideaya Biosciences, South San Francisco, CA
| | - J Lauchle
- Genentech, Inc., South San Francisco, CA; Eli Lilly, Indianapolis, IN; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Hospital Clinico Universitario de Valencia, INCLIVA, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; START Madrid-CIOCC, Hm Hospital Sanchinarro, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute / Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Ideaya Biosciences, South San Francisco, CA
| | - EW Humke
- Genentech, Inc., South San Francisco, CA; Eli Lilly, Indianapolis, IN; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Hospital Clinico Universitario de Valencia, INCLIVA, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; START Madrid-CIOCC, Hm Hospital Sanchinarro, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute / Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Ideaya Biosciences, South San Francisco, CA
| | - MR Lackner
- Genentech, Inc., South San Francisco, CA; Eli Lilly, Indianapolis, IN; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Hospital Clinico Universitario de Valencia, INCLIVA, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; START Madrid-CIOCC, Hm Hospital Sanchinarro, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute / Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Ramon y Cajal University Hospital, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Ideaya Biosciences, South San Francisco, CA
| |
Collapse
|
16
|
Bellet M, Gray K, Francis P, Láng I, Ciruelos E, Lluch A, Ángel Climent M, Catalán G, Avella A, Bohn U, González-Martin A, Zaman K, Ferrer R, Azaro A, Rajasekaran A, De la Peña L, Fleming G, Regan MM. Abstract P4-14-01: Estrogen levels in premenopausal patients (pts) with hormone-receptor positive (HR+) early breast cancer (BC) receiving adjuvant triptorelin (Trip) plus exemestane (E) or tamoxifen (T) in the SOFT trial: SOFT-EST substudy final analysis. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-14-01] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Optimal endocrine therapy for premenopausal pts with early HR+ BC may depend on complete estrogen suppression with GnRH analog, which is crucial when using concurrent aromatase inhibitors (AIs). SOFT-EST is a prospective substudy of the phase 3 SOFT trial aiming to describe estradiol (E2), estrone (E1) and estrone sulphate (E1S) during the first 4 years (y) of monthly Trip+E/T and to assess if there were suboptimally estrogen suppressed (SES) pts in the E+Trip group. Secondary objectives included associations of baseline (BL) factors with SES, early SES with later SES, and SES with disease-free survival (DFS; exploratory objective).
Methods: Patients from select centers who consented and enrolled in SOFT, selected Trip as ovarian function suppression method, and were randomized to E+Trip or T+Trip were eligible for SOFT-EST until the accrual goal (120 pts: 90 E+Trip; 30 T+Trip). Prem status for SOFT eligibility was based on local E2. Blood sampling timepoints were 0, 3, 6, 12, 18, 24, 36 & 48 months (m) until Trip stopped. Serum estrogens were measured centrally by high specificity/sensitivity GC/MSMS and were not available during the study. For 4y analyses, SES was defined as E2 levels >2.72 pg/mL in ≥2 post-BL samples (E2 levels not consistent with postmenopausal (PM) status on AIs [Smith IE, JCO 2006]), or vaginal bleeding >3m after Trip start, or pregnancy. We explored 2 additional cutoffs: >10 pg/mL (clearly inconsistent with PM status on AIs) and >20 pg/mL (inconsistent with GnRH analog-related PM status). The analysis is intention-to-treat based on E/T assignment; as-treated analyses are forthcoming.
Results: From Mar 2009 to Jan 2011,109 pts (E/T=83/26) started Trip and had ≥2 samples drawn. In pts assigned E+Trip, median reductions from BL in E1, E2 and E1S were >95% at all timepoints and significantly lower than in T+Trip. Post-BL E2 geometric mean ranged 0.8-1.3 pg/mL in E+Trip and 16.5-18.3 pg/mL in T+Trip. 21 (25%), 11 (13%) and 6 (7%) pts assigned to E+Trip had E2>2.72, >10, and >20 pg/mL in ≥2 post BL samples or vaginal bleeding (n=3), respectively. Early SES [(≥1 E2 value >2.72 pg/mL or vaginal bleeding in the firsty] predicted later SES [≥1 E2 value >2.72 or vaginal bleeding thereafter (n=1); p<0.001]. BL factors related to SES were higher E2, lower FSH and lower LH values (p=0.02, p<0.01, p<0.01 respectively). 12m FSH levels were not related to SES. In pts assigned E+Trip, after 6y median follow-up, DFS events were seen in 0 of 21 pts with SES vs 5 of 62 pts without SES.
Conclusions: Most pts on E+Trip had a profound E2 drop consistent with postmenopausal status on AI, but >20% assigned to E+Trip had ≥2 E2 values >2.72 pg/mL and 4% had vaginal bleeding, with those having higher E2, lower FSH/LH at BL being at higher risk. SES at 12m predicted subsequent SES. Few DFS events limit the ability to assess clinical relevance of SES with disease outcomes.
BL characteristicsN-109Prior chemo60 (55%)Amenorrhea39 (36%)Age <35y8 (7%) Median (range)Age, y44 (25-53)BMI, kg/m224 (22-28)Estrogen (pg/mL) E252 (7-119)E141 (24-70)E1S894 (304-1320)FSH/LH (IU/L) FSH15 (7-47)LH11 (6-26)
Citation Format: Bellet M, Gray K, Francis P, Láng I, Ciruelos E, Lluch A, Ángel Climent M, Catalán G, Avella A, Bohn U, González-Martin A, Zaman K, Ferrer R, Azaro A, Rajasekaran A, De la Peña L, Fleming G, Regan MM. Estrogen levels in premenopausal patients (pts) with hormone-receptor positive (HR+) early breast cancer (BC) receiving adjuvant triptorelin (Trip) plus exemestane (E) or tamoxifen (T) in the SOFT trial: SOFT-EST substudy final analysis [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-14-01.
Collapse
Affiliation(s)
- M Bellet
- SOFT-EST Investigators, SOLTI, and International Breast Cancer Study Group, Bern, Switzerland
| | - K Gray
- SOFT-EST Investigators, SOLTI, and International Breast Cancer Study Group, Bern, Switzerland
| | - P Francis
- SOFT-EST Investigators, SOLTI, and International Breast Cancer Study Group, Bern, Switzerland
| | - I Láng
- SOFT-EST Investigators, SOLTI, and International Breast Cancer Study Group, Bern, Switzerland
| | - E Ciruelos
- SOFT-EST Investigators, SOLTI, and International Breast Cancer Study Group, Bern, Switzerland
| | - A Lluch
- SOFT-EST Investigators, SOLTI, and International Breast Cancer Study Group, Bern, Switzerland
| | - M Ángel Climent
- SOFT-EST Investigators, SOLTI, and International Breast Cancer Study Group, Bern, Switzerland
| | - G Catalán
- SOFT-EST Investigators, SOLTI, and International Breast Cancer Study Group, Bern, Switzerland
| | - A Avella
- SOFT-EST Investigators, SOLTI, and International Breast Cancer Study Group, Bern, Switzerland
| | - U Bohn
- SOFT-EST Investigators, SOLTI, and International Breast Cancer Study Group, Bern, Switzerland
| | - A González-Martin
- SOFT-EST Investigators, SOLTI, and International Breast Cancer Study Group, Bern, Switzerland
| | - K Zaman
- SOFT-EST Investigators, SOLTI, and International Breast Cancer Study Group, Bern, Switzerland
| | - R Ferrer
- SOFT-EST Investigators, SOLTI, and International Breast Cancer Study Group, Bern, Switzerland
| | - A Azaro
- SOFT-EST Investigators, SOLTI, and International Breast Cancer Study Group, Bern, Switzerland
| | - A Rajasekaran
- SOFT-EST Investigators, SOLTI, and International Breast Cancer Study Group, Bern, Switzerland
| | - L De la Peña
- SOFT-EST Investigators, SOLTI, and International Breast Cancer Study Group, Bern, Switzerland
| | - G Fleming
- SOFT-EST Investigators, SOLTI, and International Breast Cancer Study Group, Bern, Switzerland
| | - MM Regan
- SOFT-EST Investigators, SOLTI, and International Breast Cancer Study Group, Bern, Switzerland
| |
Collapse
|
17
|
Gil-Gil M, Bellet M, Morales S, Barnadas A, Manso L, Morilla Ruiz I, Azaro A, Ciruelos Gil E, Garcia Martínez E, Marínez N, Melé M, Soler T, Villagrasa P, Pernas S. Abstract P6-15-06: SOLTI-0702 CAPRICE: Final results of a phase II study of pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as neoadjuvant chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: 5-year overall survival disease free survival and late cardiac safety. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p6-15-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Anthracycline and taxane-based chemotherapy is the standard treatment for high-risk breast cancer. However, conventional anthracyclines are not commonly used in elderly patients or those patients prone to cardiotoxicity and there is a potential risk leaving them undertreated. Pegylated liposomal doxorubicin (PLD) has comparable efficacy, but significantly less cardiotoxicity than conventional anthracyclines. We conducted a phase II trial to assess the efficacy and safety of a neoadjuvant chemotherapy (NC) based on PLD and paclitaxel (PTX) in this group of patients. The pathological complete response, breast conservative surgery (BCS) and safety data at a 35-month follow-up were published (Gil-Gil et al. Breast Cancer Res Treat 2015). Here we present the final analysis of 5-year overall survival (OS) and 5-year disease-free survival (DFS) and cardiac safety after 60 months of follow-up.
Methods:
Fifty patients with stage II (48%) and III (52%) breast cancer (seven cases were T4d) and with at least one risk factor for developing cardiotoxicity were included. NC schedule: PLD 35 mg/m2 plus cyclophosphamide 600 mg/m2 every 4 weeks for four cycles, followed by 80 mg/m2 weekly PTX for 12. Median age was 73 years old (84% were older than 65 years). Forty-eight (96%) of tumors were triple negative (TN). Secondary objectives included 5-year DFS, 5year OS and cardiac safety measured by a decrease in left ventricular ejection fraction (LVEF), electrocardiogram (ECG) anda cardiac questionnaire performed every 3 months during the first year, every 6 months year 2-3 and every 12 months year 4-5 of follow-up.
Results: Forty-eight patients (96%) completed the 4 cycles of PLD plus CPM, while only 26 patients (52%) could complete the 12 weeks of PTX. Forty-six patients (92%) underwent surgery. After surgery: 27 patients received radiotherapy, 2 letrozole and 1 trastuzumab. The 5-year OS was 56% (95% CI 41.2-68.4) and the 5-year DFS was 54.4% [95% CI: 38.3-67.9].No significant decrease in LVEF was seen (mean baseline LVEF was 66.6 (52-86) and mean LVEF after 60 months was 66 (54.5-73). Four patients (8%) developed cardiotoxicity (in 2 cases G3). There were 5 non-cancer deaths (10%): 3 during treatment (all in patients > 80 years: a sudden death one month after surgery, a haemorrhagic stroke 30 days after completing chemotherapy and a non-neutropenic pneumonia); and 2 during follow-up (1 Amyotrophic Lateral Sclerosis and 1 intestinal ischemia).
Conclusions:
PLD followed by PTX as NC was feasible in a fragile population of patients who were not candidates for conventional doxorubicin. The 5 year DFS and 5 year OS in elderly patients with bulky TN tumors were similar tothe reported in the literature. This regimen could be an option for the neoadjuvant treatment of cardiotoxicity-prone patients or elderly patients who present high-risk breast cancer.
Citation Format: Gil-Gil M, Bellet M, Morales S, Barnadas A, Manso L, Morilla Ruiz I, Azaro A, Ciruelos Gil E, Garcia Martínez E, Marínez N, Melé M, Soler T, Villagrasa P, Pernas S. SOLTI-0702 CAPRICE: Final results of a phase II study of pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as neoadjuvant chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: 5-year overall survival disease free survival and late cardiac safety [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P6-15-06.
Collapse
Affiliation(s)
- M Gil-Gil
- Institut Català d'Oncologia, IDIBELL, L' Hospitalet, Spain; Hospital Vall d´Hebron, Barcelona, Spain; Hospital Arnau de Vilanova, Leida, Spain; Hospital de Sant Pau, Barcelona, Spain; Hospital. 12 de Octubre, Madrid, Spain; Hospital. JM Morales Messeguer, Murcia, Spain; Hospital Ramón y Cajal, Madrid, Spain; Hospital Sant Joan, Reus, Spain; Hospital Universitari de Bellvitge, Barcelona, Spain; SOLTI, Barcelona, Spain
| | - M Bellet
- Institut Català d'Oncologia, IDIBELL, L' Hospitalet, Spain; Hospital Vall d´Hebron, Barcelona, Spain; Hospital Arnau de Vilanova, Leida, Spain; Hospital de Sant Pau, Barcelona, Spain; Hospital. 12 de Octubre, Madrid, Spain; Hospital. JM Morales Messeguer, Murcia, Spain; Hospital Ramón y Cajal, Madrid, Spain; Hospital Sant Joan, Reus, Spain; Hospital Universitari de Bellvitge, Barcelona, Spain; SOLTI, Barcelona, Spain
| | - S Morales
- Institut Català d'Oncologia, IDIBELL, L' Hospitalet, Spain; Hospital Vall d´Hebron, Barcelona, Spain; Hospital Arnau de Vilanova, Leida, Spain; Hospital de Sant Pau, Barcelona, Spain; Hospital. 12 de Octubre, Madrid, Spain; Hospital. JM Morales Messeguer, Murcia, Spain; Hospital Ramón y Cajal, Madrid, Spain; Hospital Sant Joan, Reus, Spain; Hospital Universitari de Bellvitge, Barcelona, Spain; SOLTI, Barcelona, Spain
| | - A Barnadas
- Institut Català d'Oncologia, IDIBELL, L' Hospitalet, Spain; Hospital Vall d´Hebron, Barcelona, Spain; Hospital Arnau de Vilanova, Leida, Spain; Hospital de Sant Pau, Barcelona, Spain; Hospital. 12 de Octubre, Madrid, Spain; Hospital. JM Morales Messeguer, Murcia, Spain; Hospital Ramón y Cajal, Madrid, Spain; Hospital Sant Joan, Reus, Spain; Hospital Universitari de Bellvitge, Barcelona, Spain; SOLTI, Barcelona, Spain
| | - L Manso
- Institut Català d'Oncologia, IDIBELL, L' Hospitalet, Spain; Hospital Vall d´Hebron, Barcelona, Spain; Hospital Arnau de Vilanova, Leida, Spain; Hospital de Sant Pau, Barcelona, Spain; Hospital. 12 de Octubre, Madrid, Spain; Hospital. JM Morales Messeguer, Murcia, Spain; Hospital Ramón y Cajal, Madrid, Spain; Hospital Sant Joan, Reus, Spain; Hospital Universitari de Bellvitge, Barcelona, Spain; SOLTI, Barcelona, Spain
| | - I Morilla Ruiz
- Institut Català d'Oncologia, IDIBELL, L' Hospitalet, Spain; Hospital Vall d´Hebron, Barcelona, Spain; Hospital Arnau de Vilanova, Leida, Spain; Hospital de Sant Pau, Barcelona, Spain; Hospital. 12 de Octubre, Madrid, Spain; Hospital. JM Morales Messeguer, Murcia, Spain; Hospital Ramón y Cajal, Madrid, Spain; Hospital Sant Joan, Reus, Spain; Hospital Universitari de Bellvitge, Barcelona, Spain; SOLTI, Barcelona, Spain
| | - A Azaro
- Institut Català d'Oncologia, IDIBELL, L' Hospitalet, Spain; Hospital Vall d´Hebron, Barcelona, Spain; Hospital Arnau de Vilanova, Leida, Spain; Hospital de Sant Pau, Barcelona, Spain; Hospital. 12 de Octubre, Madrid, Spain; Hospital. JM Morales Messeguer, Murcia, Spain; Hospital Ramón y Cajal, Madrid, Spain; Hospital Sant Joan, Reus, Spain; Hospital Universitari de Bellvitge, Barcelona, Spain; SOLTI, Barcelona, Spain
| | - E Ciruelos Gil
- Institut Català d'Oncologia, IDIBELL, L' Hospitalet, Spain; Hospital Vall d´Hebron, Barcelona, Spain; Hospital Arnau de Vilanova, Leida, Spain; Hospital de Sant Pau, Barcelona, Spain; Hospital. 12 de Octubre, Madrid, Spain; Hospital. JM Morales Messeguer, Murcia, Spain; Hospital Ramón y Cajal, Madrid, Spain; Hospital Sant Joan, Reus, Spain; Hospital Universitari de Bellvitge, Barcelona, Spain; SOLTI, Barcelona, Spain
| | - E Garcia Martínez
- Institut Català d'Oncologia, IDIBELL, L' Hospitalet, Spain; Hospital Vall d´Hebron, Barcelona, Spain; Hospital Arnau de Vilanova, Leida, Spain; Hospital de Sant Pau, Barcelona, Spain; Hospital. 12 de Octubre, Madrid, Spain; Hospital. JM Morales Messeguer, Murcia, Spain; Hospital Ramón y Cajal, Madrid, Spain; Hospital Sant Joan, Reus, Spain; Hospital Universitari de Bellvitge, Barcelona, Spain; SOLTI, Barcelona, Spain
| | - N Marínez
- Institut Català d'Oncologia, IDIBELL, L' Hospitalet, Spain; Hospital Vall d´Hebron, Barcelona, Spain; Hospital Arnau de Vilanova, Leida, Spain; Hospital de Sant Pau, Barcelona, Spain; Hospital. 12 de Octubre, Madrid, Spain; Hospital. JM Morales Messeguer, Murcia, Spain; Hospital Ramón y Cajal, Madrid, Spain; Hospital Sant Joan, Reus, Spain; Hospital Universitari de Bellvitge, Barcelona, Spain; SOLTI, Barcelona, Spain
| | - M Melé
- Institut Català d'Oncologia, IDIBELL, L' Hospitalet, Spain; Hospital Vall d´Hebron, Barcelona, Spain; Hospital Arnau de Vilanova, Leida, Spain; Hospital de Sant Pau, Barcelona, Spain; Hospital. 12 de Octubre, Madrid, Spain; Hospital. JM Morales Messeguer, Murcia, Spain; Hospital Ramón y Cajal, Madrid, Spain; Hospital Sant Joan, Reus, Spain; Hospital Universitari de Bellvitge, Barcelona, Spain; SOLTI, Barcelona, Spain
| | - T Soler
- Institut Català d'Oncologia, IDIBELL, L' Hospitalet, Spain; Hospital Vall d´Hebron, Barcelona, Spain; Hospital Arnau de Vilanova, Leida, Spain; Hospital de Sant Pau, Barcelona, Spain; Hospital. 12 de Octubre, Madrid, Spain; Hospital. JM Morales Messeguer, Murcia, Spain; Hospital Ramón y Cajal, Madrid, Spain; Hospital Sant Joan, Reus, Spain; Hospital Universitari de Bellvitge, Barcelona, Spain; SOLTI, Barcelona, Spain
| | - P Villagrasa
- Institut Català d'Oncologia, IDIBELL, L' Hospitalet, Spain; Hospital Vall d´Hebron, Barcelona, Spain; Hospital Arnau de Vilanova, Leida, Spain; Hospital de Sant Pau, Barcelona, Spain; Hospital. 12 de Octubre, Madrid, Spain; Hospital. JM Morales Messeguer, Murcia, Spain; Hospital Ramón y Cajal, Madrid, Spain; Hospital Sant Joan, Reus, Spain; Hospital Universitari de Bellvitge, Barcelona, Spain; SOLTI, Barcelona, Spain
| | - S Pernas
- Institut Català d'Oncologia, IDIBELL, L' Hospitalet, Spain; Hospital Vall d´Hebron, Barcelona, Spain; Hospital Arnau de Vilanova, Leida, Spain; Hospital de Sant Pau, Barcelona, Spain; Hospital. 12 de Octubre, Madrid, Spain; Hospital. JM Morales Messeguer, Murcia, Spain; Hospital Ramón y Cajal, Madrid, Spain; Hospital Sant Joan, Reus, Spain; Hospital Universitari de Bellvitge, Barcelona, Spain; SOLTI, Barcelona, Spain
| |
Collapse
|
18
|
Hurtado A, Wang S, Gilfillan S, Norum JH, Bergholtz H, Singh SK, Fosdahl AM, Nord S, Engebraten O, Lingjaerde OC, Bellet M, Sørlie T. Abstract P4-03-03: Not presented. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p4-03-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was not presented at the symposium.
Collapse
Affiliation(s)
- A Hurtado
- Universtiy of Oslo, Oslo, Norway; Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - S Wang
- Universtiy of Oslo, Oslo, Norway; Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - S Gilfillan
- Universtiy of Oslo, Oslo, Norway; Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - JH Norum
- Universtiy of Oslo, Oslo, Norway; Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - H Bergholtz
- Universtiy of Oslo, Oslo, Norway; Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - SK Singh
- Universtiy of Oslo, Oslo, Norway; Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - AM Fosdahl
- Universtiy of Oslo, Oslo, Norway; Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - S Nord
- Universtiy of Oslo, Oslo, Norway; Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - O Engebraten
- Universtiy of Oslo, Oslo, Norway; Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - OC Lingjaerde
- Universtiy of Oslo, Oslo, Norway; Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - M Bellet
- Universtiy of Oslo, Oslo, Norway; Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - T Sørlie
- Universtiy of Oslo, Oslo, Norway; Vall d'Hebron Institute of Oncology, Barcelona, Spain
| |
Collapse
|
19
|
Dickler MN, Villanueva R, Perez Fidalgo JA, Mayer IA, Boni V, Winer EP, Hamilton EP, Bellet M, Urruticoechea A, Gonzalez-Martin A, Cortes J, Martin M, Giltnane J, Gates M, Cheeti S, Fredrickson J, Wang X, Friedman LS, Spoerke JM, Metcalfe C, Liu L, Li R, Morley R, McCurry U, Chan IT, Mueller L, Milan S, Lauchle J, Humke EW, Bardia A. Abstract PD5-10: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-0927, in postmenopausal women with estrogen receptor positive (ER+) HER2-negative metastatic breast cancer (BC). Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-pd5-10] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Modulation of estrogen activity and/or synthesis is the mainstay therapeutic strategy in the treatment of ER+ BC. However, despite the effectiveness of available endocrine therapies, many patients ultimately relapse or develop resistance to these agents via estrogen-dependent and estrogen-independent mechanisms, including mutations in ESR1 affecting the ER ligand binding domain that drive ER-dependent transcription and proliferation in the absence of estrogen. ER antagonists that are efficacious against ligand-dependent and ligand-independent, constitutively active ESR1 mutant tumors may be of substantial therapeutic benefit. GDC-0927 (formerly known as SRN-927) is a novel, potent, non-steroidal, orally bioavailable, selective ER antagonist/ER degrader (SERD) that induces tumor regression in ER+ BC patient-derived xenograft models.
Methods: A phase I dose escalation study with 3+3 design was conductedin postmenopausal women with ER+ (HER2-) metastatic BC (progressing ≥ 6 months on endocrine therapy and with ≤ 2 prior chemotherapies in the advanced or metastatic setting) to determine the safety, pharmacokinetics (PK) and the recommended Phase 2 dose (RP2D) of GDC-0927. Pharmacodynamic (PD) activity was assessed with [18F]-fluoroestradiol (FES)-PET scans. Plasma PK samples (after single dose and at steady state), CT scans, and when feasible, pre and on-study tumor biopsies were obtained
Results: From March 16, 2015 to March 17, 2017 patients (pts) with a median age of 53 years (range 44-69) and a median number of prior therapies for MBC 4 (range 1-7) were enrolled at 3 total daily dose levels (600, 1000, 1400 mg) once daily (QD) given orally with fasting (n = 12). Increases in GDC-0927 exposure were approximately dose proportional. Treatment related adverse events (AEs) were all grade 1 or 2. The most common treatment-related AEs were nausea (54%, n = 7), diarrhea (46%, n = 6), elevated aspartate aminotransferase (39%, n = 5) and anemia, constipation, (each 31%, n = 4). Treatment interruption was required for 2 pts due to nausea and vomiting. Of those pts with FES-PET avid disease at baseline (9 of 12), all post-therapy scans showed complete or near complete (> 90%) suppression of FES uptake to background levels, including pts with ESR1 mutations. Evidence of reduced ER levels and Ki67 staining was observed in on-treatment biopsies. Five of 12 pts (1 at 600 mg and 4 at 1400 mg) were on study ≥ 24 weeks (CBR = 41.6 %) with the best overall response of stable disease with 1 patient (ESR1 mt+ D538G) on study for over 490 days. There were no dose limiting toxicities and no SAEs related to study drug. R2PD was 1400 mg and was selected for single arm dose-expansion which is now complete with last patient enrolled on March 17, 2017. Updated results from dose-escalation and dose-expansion will be presented at the meeting (N = 43).
Conclusions: GDC-0927 appears well-tolerated to date with PK exposure supporting QD dosing, evidence of robust PD target engagement, and encouraging anti-tumor activity in heavily pretreated pts with advanced or metastatic ER+ BC, including pts with ESR1 mutations.
Citation Format: Dickler MN, Villanueva R, Perez Fidalgo JA, Mayer IA, Boni V, Winer EP, Hamilton EP, Bellet M, Urruticoechea A, Gonzalez-Martin A, Cortes J, Martin M, Giltnane J, Gates M, Cheeti S, Fredrickson J, Wang X, Friedman LS, Spoerke JM, Metcalfe C, Liu L, Li R, Morley R, McCurry U, Chan IT, Mueller L, Milan S, Lauchle J, Humke EW, Bardia A. A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-0927, in postmenopausal women with estrogen receptor positive (ER+) HER2-negative metastatic breast cancer (BC) [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr PD5-10.
Collapse
Affiliation(s)
- MN Dickler
- Memorial Sloan Kettering Cancer Center, New York, NY; Institut Català d'Oncologia- Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Clinico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; HM Sanchinarro – CIOCC, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Hospital Universitario Ramon y Cajal, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - R Villanueva
- Memorial Sloan Kettering Cancer Center, New York, NY; Institut Català d'Oncologia- Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Clinico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; HM Sanchinarro – CIOCC, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Hospital Universitario Ramon y Cajal, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - JA Perez Fidalgo
- Memorial Sloan Kettering Cancer Center, New York, NY; Institut Català d'Oncologia- Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Clinico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; HM Sanchinarro – CIOCC, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Hospital Universitario Ramon y Cajal, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - IA Mayer
- Memorial Sloan Kettering Cancer Center, New York, NY; Institut Català d'Oncologia- Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Clinico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; HM Sanchinarro – CIOCC, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Hospital Universitario Ramon y Cajal, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - V Boni
- Memorial Sloan Kettering Cancer Center, New York, NY; Institut Català d'Oncologia- Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Clinico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; HM Sanchinarro – CIOCC, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Hospital Universitario Ramon y Cajal, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - EP Winer
- Memorial Sloan Kettering Cancer Center, New York, NY; Institut Català d'Oncologia- Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Clinico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; HM Sanchinarro – CIOCC, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Hospital Universitario Ramon y Cajal, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - EP Hamilton
- Memorial Sloan Kettering Cancer Center, New York, NY; Institut Català d'Oncologia- Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Clinico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; HM Sanchinarro – CIOCC, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Hospital Universitario Ramon y Cajal, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - M Bellet
- Memorial Sloan Kettering Cancer Center, New York, NY; Institut Català d'Oncologia- Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Clinico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; HM Sanchinarro – CIOCC, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Hospital Universitario Ramon y Cajal, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - A Urruticoechea
- Memorial Sloan Kettering Cancer Center, New York, NY; Institut Català d'Oncologia- Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Clinico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; HM Sanchinarro – CIOCC, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Hospital Universitario Ramon y Cajal, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - A Gonzalez-Martin
- Memorial Sloan Kettering Cancer Center, New York, NY; Institut Català d'Oncologia- Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Clinico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; HM Sanchinarro – CIOCC, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Hospital Universitario Ramon y Cajal, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - J Cortes
- Memorial Sloan Kettering Cancer Center, New York, NY; Institut Català d'Oncologia- Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Clinico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; HM Sanchinarro – CIOCC, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Hospital Universitario Ramon y Cajal, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - M Martin
- Memorial Sloan Kettering Cancer Center, New York, NY; Institut Català d'Oncologia- Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Clinico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; HM Sanchinarro – CIOCC, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Hospital Universitario Ramon y Cajal, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - J Giltnane
- Memorial Sloan Kettering Cancer Center, New York, NY; Institut Català d'Oncologia- Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Clinico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; HM Sanchinarro – CIOCC, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Hospital Universitario Ramon y Cajal, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - M Gates
- Memorial Sloan Kettering Cancer Center, New York, NY; Institut Català d'Oncologia- Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Clinico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; HM Sanchinarro – CIOCC, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Hospital Universitario Ramon y Cajal, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - S Cheeti
- Memorial Sloan Kettering Cancer Center, New York, NY; Institut Català d'Oncologia- Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Clinico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; HM Sanchinarro – CIOCC, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Hospital Universitario Ramon y Cajal, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - J Fredrickson
- Memorial Sloan Kettering Cancer Center, New York, NY; Institut Català d'Oncologia- Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Clinico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; HM Sanchinarro – CIOCC, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Hospital Universitario Ramon y Cajal, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - X Wang
- Memorial Sloan Kettering Cancer Center, New York, NY; Institut Català d'Oncologia- Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Clinico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; HM Sanchinarro – CIOCC, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Hospital Universitario Ramon y Cajal, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - LS Friedman
- Memorial Sloan Kettering Cancer Center, New York, NY; Institut Català d'Oncologia- Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Clinico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; HM Sanchinarro – CIOCC, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Hospital Universitario Ramon y Cajal, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - JM Spoerke
- Memorial Sloan Kettering Cancer Center, New York, NY; Institut Català d'Oncologia- Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Clinico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; HM Sanchinarro – CIOCC, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Hospital Universitario Ramon y Cajal, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - C Metcalfe
- Memorial Sloan Kettering Cancer Center, New York, NY; Institut Català d'Oncologia- Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Clinico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; HM Sanchinarro – CIOCC, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Hospital Universitario Ramon y Cajal, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - L Liu
- Memorial Sloan Kettering Cancer Center, New York, NY; Institut Català d'Oncologia- Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Clinico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; HM Sanchinarro – CIOCC, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Hospital Universitario Ramon y Cajal, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - R Li
- Memorial Sloan Kettering Cancer Center, New York, NY; Institut Català d'Oncologia- Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Clinico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; HM Sanchinarro – CIOCC, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Hospital Universitario Ramon y Cajal, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - R Morley
- Memorial Sloan Kettering Cancer Center, New York, NY; Institut Català d'Oncologia- Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Clinico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; HM Sanchinarro – CIOCC, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Hospital Universitario Ramon y Cajal, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - U McCurry
- Memorial Sloan Kettering Cancer Center, New York, NY; Institut Català d'Oncologia- Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Clinico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; HM Sanchinarro – CIOCC, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Hospital Universitario Ramon y Cajal, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - IT Chan
- Memorial Sloan Kettering Cancer Center, New York, NY; Institut Català d'Oncologia- Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Clinico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; HM Sanchinarro – CIOCC, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Hospital Universitario Ramon y Cajal, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - L Mueller
- Memorial Sloan Kettering Cancer Center, New York, NY; Institut Català d'Oncologia- Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Clinico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; HM Sanchinarro – CIOCC, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Hospital Universitario Ramon y Cajal, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - S Milan
- Memorial Sloan Kettering Cancer Center, New York, NY; Institut Català d'Oncologia- Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Clinico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; HM Sanchinarro – CIOCC, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Hospital Universitario Ramon y Cajal, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - J Lauchle
- Memorial Sloan Kettering Cancer Center, New York, NY; Institut Català d'Oncologia- Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Clinico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; HM Sanchinarro – CIOCC, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Hospital Universitario Ramon y Cajal, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - EW Humke
- Memorial Sloan Kettering Cancer Center, New York, NY; Institut Català d'Oncologia- Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Clinico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; HM Sanchinarro – CIOCC, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Hospital Universitario Ramon y Cajal, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - A Bardia
- Memorial Sloan Kettering Cancer Center, New York, NY; Institut Català d'Oncologia- Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Clinico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain; Vanderbilt University Medical Center, Nashville, TN; HM Sanchinarro – CIOCC, Madrid, Spain; Dana Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Onkologikoa, San Sebastian, Spain; Clinica Universidad de Navarra, Madrid, Spain; Hospital Universitario Ramon y Cajal, Madrid, Spain; Hospital General Universitario Gregorio Marañon, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| |
Collapse
|
20
|
Fleming G, Francis PA, Láng I, Ciruelos EM, Bellet M, Bonnefoi HR, Climent MA, Pavesi L, Burstein HJ, Martino S, Davidson NE, Geyer CE, Walley BA, Coleman RE, Kerbrat P, Buchholz S, Ingle JN, Rabaglio-Poretti M, Colleoni M, Regan MM. Abstract GS4-03: Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Update of the SOFT trial. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-gs4-03] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The primary results of SOFT at 5.6 years median follow-up found adding OFS to T did not provide a significant benefit in the overall study population of premenopausal women with HR+ BC (Francis et al, NEJM 2015). For those women at sufficient risk for recurrence to warrant adjuvant chemotherapy (CT) and who remained premenopausal, the addition of OFS improved disease outcomes. Follow-up was immature for overall survival (OS). We report a planned update with visit cut-off of 31Dec16 after 8 yrs median follow-up.
Methods: SOFT randomized premenopausal women with HR+ BC from Nov 2003 to Jan 2011 to 5 yrs of T vs T+OFS vs Exemestane(E)+OFS. OFS was by choice of GnRH agonist triptorelin, oophorectomy or ovarian irradiation. SOFT was stratified by the use of prior CT; 47% received no CT and 53% remained premenopausal after prior CT, determined by premenopausal estradiol level within 8 months of CT completion. The primary endpoint was invasive disease-free survival (DFS; randomization until invasive local, regional, distant recurrence or contralateral breast; invasive second malignancy; death). Secondary endpoints included invasive breast cancer-free interval (BCFI), distant recurrence-free interval (DRFI) and OS. NCT00066690.
Results: DFS for patients assigned T+OFS (n=1015) was significantly improved over T (n=1018; HR=0.76 [95%CI 0.62-0.93]) and 8yr DFS was 83.2% vs 78.9%, respectively; BCFI and DRFI results were supportive (see Table). Hazard ratios for these 3 endpoints showed no heterogeneity by use of prior CT. For patients with prior CT, 8yr DFS was 76.7% with T+OFS vs 71.4% with T (Δ=5.3%); in those without CT, 8yr DFS was 90.6% vs 87.4% (Δ=3.2%). E+OFS (n=1014) improved outcomes relative to T (Table); 8yr DFS for E+OFS was 85.9% (80.4% with use of prior CT and 92.5% for those without CT). OS was improved with T+OFS vs T (8yr OS 93.3% vs 91.5%). 8yr OS was 92.1% with E+OFS. 201/225 deaths occurred in women with prior CT. For women without CT there have been 10, 5 and 9 deaths in the T+OFS, T and E+OFS groups (total n=1419), respectively, only half of these deaths after breast cancer event.
N. EventsHazard Ratio (95% CI)Endpoint(3 arms)T+OFS vs TE+OFS vs TDFS5180.76 (0.62-0.93) P=0.0090.65 (0.53-0.81)BCFI4370.76 (0.61-0.95)0.64 (0.51-0.81)DRFI3060.86 (0.66-1.13)0.73 (0.55-0.96)OS2250.67 (0.48-0.92)0.85 (0.62-1.15)
Overall toxicity was worse with T+ OFS than with T, including 32% vs 25% grade 3+ targeted AEs. Early cessation of tamoxifen occurred for 19% assigned T+OFS and 22% of women assigned T; the cumulative incidence of early cessation of triptorelin on the T+OFS arm was 23% by 4yrs. Early cessation of exemestane occurred for 28% and of triptorelin for 21% by 4yrs on the E+OFS arm.
Conclusions: With additional follow-up to a median of 8yrs, SOFT further supports the value of OFS for some premenopausal women. Follow-up continues, which will further clarify the safety and the benefit of OFS for late recurrence and overall survival. Oncologists appear to be able to select a low risk group (no chemotherapy) for whom treatment escalation is unlikely to improve survival.
Citation Format: Fleming G, Francis PA, Láng I, Ciruelos EM, Bellet M, Bonnefoi HR, Climent MA, Pavesi L, Burstein HJ, Martino S, Davidson NE, Geyer Jr CE, Walley BA, Coleman RE, Kerbrat P, Buchholz S, Ingle JN, Rabaglio-Poretti M, Colleoni M, Regan MM. Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Update of the SOFT trial [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr GS4-03.
Collapse
Affiliation(s)
- G Fleming
- SOFT Investigators, International Breast Cancer Study Group, Breast International Group, and North American Breast Cancer Group
| | - PA Francis
- SOFT Investigators, International Breast Cancer Study Group, Breast International Group, and North American Breast Cancer Group
| | - I Láng
- SOFT Investigators, International Breast Cancer Study Group, Breast International Group, and North American Breast Cancer Group
| | - EM Ciruelos
- SOFT Investigators, International Breast Cancer Study Group, Breast International Group, and North American Breast Cancer Group
| | - M Bellet
- SOFT Investigators, International Breast Cancer Study Group, Breast International Group, and North American Breast Cancer Group
| | - HR Bonnefoi
- SOFT Investigators, International Breast Cancer Study Group, Breast International Group, and North American Breast Cancer Group
| | - MA Climent
- SOFT Investigators, International Breast Cancer Study Group, Breast International Group, and North American Breast Cancer Group
| | - L Pavesi
- SOFT Investigators, International Breast Cancer Study Group, Breast International Group, and North American Breast Cancer Group
| | - HJ Burstein
- SOFT Investigators, International Breast Cancer Study Group, Breast International Group, and North American Breast Cancer Group
| | - S Martino
- SOFT Investigators, International Breast Cancer Study Group, Breast International Group, and North American Breast Cancer Group
| | - NE Davidson
- SOFT Investigators, International Breast Cancer Study Group, Breast International Group, and North American Breast Cancer Group
| | - CE Geyer
- SOFT Investigators, International Breast Cancer Study Group, Breast International Group, and North American Breast Cancer Group
| | - BA Walley
- SOFT Investigators, International Breast Cancer Study Group, Breast International Group, and North American Breast Cancer Group
| | - RE Coleman
- SOFT Investigators, International Breast Cancer Study Group, Breast International Group, and North American Breast Cancer Group
| | - P Kerbrat
- SOFT Investigators, International Breast Cancer Study Group, Breast International Group, and North American Breast Cancer Group
| | - S Buchholz
- SOFT Investigators, International Breast Cancer Study Group, Breast International Group, and North American Breast Cancer Group
| | - JN Ingle
- SOFT Investigators, International Breast Cancer Study Group, Breast International Group, and North American Breast Cancer Group
| | - M Rabaglio-Poretti
- SOFT Investigators, International Breast Cancer Study Group, Breast International Group, and North American Breast Cancer Group
| | - M Colleoni
- SOFT Investigators, International Breast Cancer Study Group, Breast International Group, and North American Breast Cancer Group
| | - MM Regan
- SOFT Investigators, International Breast Cancer Study Group, Breast International Group, and North American Breast Cancer Group
| |
Collapse
|
21
|
Palafox M, Herrera M, Bellet M, Arribas J, Saura C, Di Tomaso E, Turner N, Cortés J, Baselga J, Serra V. Identification of CDK4/6-response biomarkers using estrogen receptor-positive breast cancer patient-derived xenografts (PDX). Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)61474-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
22
|
Zamora E, Aura C, Perez-Garcia J, Prudkin L, Meire A, Muñoz Cosuelo E, Jimenez J, Diaz-Delgado M, Ortega V, Soberino J, Farinas L, Salva F, Bellet M, Cruz C, Gomez P, Oliveira M, Vidal MJ, Saura C, Cortes J, Nuciforo P. Abstract P4-09-02: Concordance in fibroblast growth factor receptor 1 (FGFR1) and 2 (FGFR2) status in breast cancer during tumor progression. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p4-09-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: In recent years, changes in HER2 and hormone receptor (HR) status between primary and metastatic breast cancer (BC) have been extensively reported. Additionally, current advances in BC biology have identified emerging biomarkers with clinical and prognostic implications, particularly the PI3K-AKT-mTOR and the FGF/FGFR pathways. FGFR1 and FGFR2 gene amplifications represent the most frequent genomic aberrations in BC. The 8p11-12 chromosomal region harboring the FGFR1 gene locus is amplified in about 10-18% of human BC, mainly in HR-positive/HER2-negative subtype, whereas the FGFR2 gene, located on chromosome 10q26, is amplified in approximately 4% of triple negative BC. To our knowledge, there is a lack of data regarding the concordance of FGFR1 and FGFR2 status between primary and metastatic tumors.
METHODS: Tumor samples from 205 and 67 advanced BC patients diagnosed at our institution between 2010 and 2014 were screened for FGFR1 and FGFR2 amplification by FISH using the ZytoLight SPEC FGFR1/CEN8 and FGFR2/CEN10 probes, respectively. FGFR1 and FGFR2 amplification were defined as a ratio of FGFR1/CEN8 and FGFR2/CEN10 ≥ 2.2. We investigated the correlation of FGFR1 and FGFR2 status between primary and metastatic tumors in 16 and 13 patients, respectively, for whom paired samples were available.
RESULTS: A total of 47 FGFR1-amplified patients (22.9%) and 3 FGFR2-amplified patients (4.5%) were identified. Patients with paired samples were classified according to FGFR1 and FGFR2 status in primary tumor. Regarding FGFR1 amplification, eight patients were FGFR1-amplified and eight were FGFR1-non-amplified. One patient in each group showed discordance in FGFR1 status in the metastatic tumor. Overall rate of concordance between primary and metastatic tumors was 87.5% (14/16). In relation to FGFR2 status, two patients were FGFR2-amplified and 11 were FGFR2-non-amplified with a 100% overall rate of concordance between paired samples (13/13). These data are summarized in Table 1.
Table 1 Metastases PrimaryAmplifiedNon-amplifiedFGFR1Amplified (n=8)71 Non-amplified (n=8)17FGFR2Amplified (n=2)20 Non-amplified (n=11)011
CONCLUSIONS: Results suggest a high concordance in FGFR1 and FGFR2 status between primary and metastatic BC. The potential impact of these findings on the development of FGFR inhibitors merits further investigation.
Citation Format: Zamora E, Aura C, Perez-Garcia J, Prudkin L, Meire A, Muñoz Cosuelo E, Jimenez J, Diaz-Delgado M, Ortega V, Soberino J, Farinas L, Salva F, Bellet M, Cruz C, Gomez P, Oliveira M, Vidal MJ, Saura C, Cortes J, Nuciforo P. Concordance in fibroblast growth factor receptor 1 (FGFR1) and 2 (FGFR2) status in breast cancer during tumor progression. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-09-02.
Collapse
Affiliation(s)
- E Zamora
- Breast Cancer Unit, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; Molecular Oncology Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - C Aura
- Breast Cancer Unit, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; Molecular Oncology Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - J Perez-Garcia
- Breast Cancer Unit, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; Molecular Oncology Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - L Prudkin
- Breast Cancer Unit, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; Molecular Oncology Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - A Meire
- Breast Cancer Unit, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; Molecular Oncology Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - E Muñoz Cosuelo
- Breast Cancer Unit, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; Molecular Oncology Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - J Jimenez
- Breast Cancer Unit, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; Molecular Oncology Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - M Diaz-Delgado
- Breast Cancer Unit, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; Molecular Oncology Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - V Ortega
- Breast Cancer Unit, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; Molecular Oncology Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - J Soberino
- Breast Cancer Unit, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; Molecular Oncology Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - L Farinas
- Breast Cancer Unit, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; Molecular Oncology Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - F Salva
- Breast Cancer Unit, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; Molecular Oncology Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - M Bellet
- Breast Cancer Unit, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; Molecular Oncology Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - C Cruz
- Breast Cancer Unit, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; Molecular Oncology Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - P Gomez
- Breast Cancer Unit, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; Molecular Oncology Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - M Oliveira
- Breast Cancer Unit, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; Molecular Oncology Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - MJ Vidal
- Breast Cancer Unit, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; Molecular Oncology Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - C Saura
- Breast Cancer Unit, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; Molecular Oncology Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - J Cortes
- Breast Cancer Unit, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; Molecular Oncology Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - P Nuciforo
- Breast Cancer Unit, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; Molecular Oncology Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| |
Collapse
|
23
|
Serra V, Cruz C, Bruna A, Ibrahim YH, Vivancos A, Vivancos A, Nuciforo P, Bellet M, Gómez P, Pérez JM, Saura C, Vidal M, Serres X, Rueda OM, Peg V, Caldas C, O'Connor MJ, Baselga J, Cortés J. Abstract P4-07-04: PARP1/2 inhibition in a subset of triple negative breast cancer (TNBC) patient-derived tumor xenografts (PDX) identifies predictive biomarkers of response. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p4-07-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: BRCA1/2 mutation carriers (gBRCA) have a higher risk of breast or ovarian cancer, since BRCA1/2 mutation results in impaired high-fidelity DNA repair by homologous recombination (HR) and subsequently genetic instability. In non-gBRCA TNBC, HR deficiency occurs at the somatic level, by means of BRCA1 mutation, BRCA1 epigenetic loss or mutation in other HR-associated genes. Because PARP1/2 inhibitors (PARPi) are well-tolerated and active anti-cancer agents in the advanced setting of gBRCA tumors, we sought to expand their applicability by identifying response biomarkers in TNBC.
Methods: We have assessed the antitumor response of the PARP1/2 inhibitor olaparib as single agent in a panel of 12 primary and advanced TNBC PDX models. On PDXs exhibiting primary sensitivity to olaparib, we have developed models of acquired resistance by continuous exposure to the drug and identifying progression on treatment. We have characterized the models through targeted sequencing and the analysis of the hypermethylation and expression levels of BRCA1 transcript to find potential correlates of drug-sensitivity.
Results: Three out of 12 PDXs (25%) treated with single agent olaparib, exhibit tumor regression or disease stabilization. BRCA1 is hypermethylated in two of these PARPi-sensitive TNBC PDX models and is associated with loss of BRCA1 mRNA expression. The third PARPi-sensitive TNBC PDX harbors a frameshift, heterozygous PALB2 mutation, which is no longer detected in the acquired resistance PDX model. Acquired resistance in the hypermethylated PDXs is under study as well as the duration of response compared to gBRCA PDX models.
Conclusions: Our study highlights that somatic HR-deficiency is frequent in TNBC and provides the basis of sensitivity to PARPi.
Citation Format: Serra V, Cruz C, Bruna A, Ibrahim YH, Vivancos A, Vivancos A, Nuciforo P, Bellet M, Gómez P, Pérez JM, Saura C, Vidal M, Serres X, Rueda OM, Peg V, Caldas C, O'Connor MJ, Baselga J, Cortés J. PARP1/2 inhibition in a subset of triple negative breast cancer (TNBC) patient-derived tumor xenografts (PDX) identifies predictive biomarkers of response. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-07-04.
Collapse
Affiliation(s)
- V Serra
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Cancer Research UK, CI (CRUK), Cambridge, United Kingdom; Vall d'Hebron University Hospital (VHUH), Barcelona, Spain; Astra Zeneca (AZ), Macclesfield, United Kingdom; Netherlands Cancer Institute (NKI), Amsterdam, Netherlands; Memorial Sloan Kettering Cancer Center (MSKCC), NY
| | - C Cruz
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Cancer Research UK, CI (CRUK), Cambridge, United Kingdom; Vall d'Hebron University Hospital (VHUH), Barcelona, Spain; Astra Zeneca (AZ), Macclesfield, United Kingdom; Netherlands Cancer Institute (NKI), Amsterdam, Netherlands; Memorial Sloan Kettering Cancer Center (MSKCC), NY
| | - A Bruna
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Cancer Research UK, CI (CRUK), Cambridge, United Kingdom; Vall d'Hebron University Hospital (VHUH), Barcelona, Spain; Astra Zeneca (AZ), Macclesfield, United Kingdom; Netherlands Cancer Institute (NKI), Amsterdam, Netherlands; Memorial Sloan Kettering Cancer Center (MSKCC), NY
| | - YH Ibrahim
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Cancer Research UK, CI (CRUK), Cambridge, United Kingdom; Vall d'Hebron University Hospital (VHUH), Barcelona, Spain; Astra Zeneca (AZ), Macclesfield, United Kingdom; Netherlands Cancer Institute (NKI), Amsterdam, Netherlands; Memorial Sloan Kettering Cancer Center (MSKCC), NY
| | - A Vivancos
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Cancer Research UK, CI (CRUK), Cambridge, United Kingdom; Vall d'Hebron University Hospital (VHUH), Barcelona, Spain; Astra Zeneca (AZ), Macclesfield, United Kingdom; Netherlands Cancer Institute (NKI), Amsterdam, Netherlands; Memorial Sloan Kettering Cancer Center (MSKCC), NY
| | - A Vivancos
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Cancer Research UK, CI (CRUK), Cambridge, United Kingdom; Vall d'Hebron University Hospital (VHUH), Barcelona, Spain; Astra Zeneca (AZ), Macclesfield, United Kingdom; Netherlands Cancer Institute (NKI), Amsterdam, Netherlands; Memorial Sloan Kettering Cancer Center (MSKCC), NY
| | - P Nuciforo
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Cancer Research UK, CI (CRUK), Cambridge, United Kingdom; Vall d'Hebron University Hospital (VHUH), Barcelona, Spain; Astra Zeneca (AZ), Macclesfield, United Kingdom; Netherlands Cancer Institute (NKI), Amsterdam, Netherlands; Memorial Sloan Kettering Cancer Center (MSKCC), NY
| | - M Bellet
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Cancer Research UK, CI (CRUK), Cambridge, United Kingdom; Vall d'Hebron University Hospital (VHUH), Barcelona, Spain; Astra Zeneca (AZ), Macclesfield, United Kingdom; Netherlands Cancer Institute (NKI), Amsterdam, Netherlands; Memorial Sloan Kettering Cancer Center (MSKCC), NY
| | - P Gómez
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Cancer Research UK, CI (CRUK), Cambridge, United Kingdom; Vall d'Hebron University Hospital (VHUH), Barcelona, Spain; Astra Zeneca (AZ), Macclesfield, United Kingdom; Netherlands Cancer Institute (NKI), Amsterdam, Netherlands; Memorial Sloan Kettering Cancer Center (MSKCC), NY
| | - JM Pérez
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Cancer Research UK, CI (CRUK), Cambridge, United Kingdom; Vall d'Hebron University Hospital (VHUH), Barcelona, Spain; Astra Zeneca (AZ), Macclesfield, United Kingdom; Netherlands Cancer Institute (NKI), Amsterdam, Netherlands; Memorial Sloan Kettering Cancer Center (MSKCC), NY
| | - C Saura
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Cancer Research UK, CI (CRUK), Cambridge, United Kingdom; Vall d'Hebron University Hospital (VHUH), Barcelona, Spain; Astra Zeneca (AZ), Macclesfield, United Kingdom; Netherlands Cancer Institute (NKI), Amsterdam, Netherlands; Memorial Sloan Kettering Cancer Center (MSKCC), NY
| | - M Vidal
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Cancer Research UK, CI (CRUK), Cambridge, United Kingdom; Vall d'Hebron University Hospital (VHUH), Barcelona, Spain; Astra Zeneca (AZ), Macclesfield, United Kingdom; Netherlands Cancer Institute (NKI), Amsterdam, Netherlands; Memorial Sloan Kettering Cancer Center (MSKCC), NY
| | - X Serres
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Cancer Research UK, CI (CRUK), Cambridge, United Kingdom; Vall d'Hebron University Hospital (VHUH), Barcelona, Spain; Astra Zeneca (AZ), Macclesfield, United Kingdom; Netherlands Cancer Institute (NKI), Amsterdam, Netherlands; Memorial Sloan Kettering Cancer Center (MSKCC), NY
| | - OM Rueda
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Cancer Research UK, CI (CRUK), Cambridge, United Kingdom; Vall d'Hebron University Hospital (VHUH), Barcelona, Spain; Astra Zeneca (AZ), Macclesfield, United Kingdom; Netherlands Cancer Institute (NKI), Amsterdam, Netherlands; Memorial Sloan Kettering Cancer Center (MSKCC), NY
| | - V Peg
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Cancer Research UK, CI (CRUK), Cambridge, United Kingdom; Vall d'Hebron University Hospital (VHUH), Barcelona, Spain; Astra Zeneca (AZ), Macclesfield, United Kingdom; Netherlands Cancer Institute (NKI), Amsterdam, Netherlands; Memorial Sloan Kettering Cancer Center (MSKCC), NY
| | - C Caldas
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Cancer Research UK, CI (CRUK), Cambridge, United Kingdom; Vall d'Hebron University Hospital (VHUH), Barcelona, Spain; Astra Zeneca (AZ), Macclesfield, United Kingdom; Netherlands Cancer Institute (NKI), Amsterdam, Netherlands; Memorial Sloan Kettering Cancer Center (MSKCC), NY
| | - MJ O'Connor
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Cancer Research UK, CI (CRUK), Cambridge, United Kingdom; Vall d'Hebron University Hospital (VHUH), Barcelona, Spain; Astra Zeneca (AZ), Macclesfield, United Kingdom; Netherlands Cancer Institute (NKI), Amsterdam, Netherlands; Memorial Sloan Kettering Cancer Center (MSKCC), NY
| | - J Baselga
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Cancer Research UK, CI (CRUK), Cambridge, United Kingdom; Vall d'Hebron University Hospital (VHUH), Barcelona, Spain; Astra Zeneca (AZ), Macclesfield, United Kingdom; Netherlands Cancer Institute (NKI), Amsterdam, Netherlands; Memorial Sloan Kettering Cancer Center (MSKCC), NY
| | - J Cortés
- Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Cancer Research UK, CI (CRUK), Cambridge, United Kingdom; Vall d'Hebron University Hospital (VHUH), Barcelona, Spain; Astra Zeneca (AZ), Macclesfield, United Kingdom; Netherlands Cancer Institute (NKI), Amsterdam, Netherlands; Memorial Sloan Kettering Cancer Center (MSKCC), NY
| |
Collapse
|
24
|
Oliveira M, Dienstmann R, Bellet M, Pérez-Garcia JM, Gómez P, Muñoz-Couselo E, Vidal M, Ortega V, Zamora E, Soberino J, Meire A, Nuciforo P, Vivancos A, Cortés J, Saura C. Abstract P2-08-13: Integrating multiplex and next generation sequencing (NGS) platforms in routine molecular profiling of metastatic breast cancer (MBC) patients (pts): Trends for enrollment in genotype-directed clinical trials (GDTs). Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p2-08-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background/aims: Multiplex or NGS platforms increase the number of mutations (mut) detected in tumor samples respect to single-gene sequencing techniques. We aimed to assess the actionable molecular alteration (ActMA) detection rate and the enrollment in GDTs derived from the integration of these platforms in routine molecular profiling of MBC pts, in addition to FISH and IHC techniques already in use. Methods: Consecutive MBC pts screened for gene mut by Sequenom (Seq) or AmpliconSeq (ASeq) were identified. Data on FGFR1 amplification (amp), PTEN IHC, and enrollment in GDTs were collected. ActMA: any mut, PTENnull (IHC score=0), or FGFR1/HER2amp for which a matched targeted drug might be available. Targeted therapy: treatment with PI3K/mTOR, novel anti-HER2, FGFR, or AKT inhibitors (inh) irrespective of having ActMA. GDT: treatment matched to ActMA. Results: From Oct2010-Apr2015, 260 pts screened (Seq 207, ASeq 53). IHC subtype: HR+/HER2- (LUM) 65%, HER2+ 13.5%, TN 19.6%, unk 1.9%. 84 samples from a metastatic site (32.3%).
ActMA / n (%)LUMHER2+TNP value (Fisher's exact test)TotalTP53*11 (31.4)1 (50)9 (52.9)0.3421 (38.9)PIK3CA44 (26)10 (28.6)4 (7.8)0.158 (22.7)FGFR1amp21 (17.4)1 (5.3)6 (16.7)0.4728 (15.9)PTENnull12 (9.3)2 (7.7)9 (25)0.0323 (12)AKT110 (5.9)1 (2.9)-0.1511 (4.3)ERBB23 (1.8)---3 (1.2)EGFR1 (0.6)-2 (4.1)-3 (1.2)ESR1*1 (3)---1 (2)KRAS2 (1.2)---2 (0.8)Denominators vary according to platform. *Amplicon only
Proportion of PIK3CAmut was similar irrespective of the site of analysis (primary 25.5%, metastasis 21.4%; P=0.63) and platform (Seq 22.2%, ASeq 24.5%, P=0.72). ASeq detected more mutations in actionable genes than Seq (36% vs. 29%, P=0.01). At least 1 ActMA (range 0-3) was found in 53.5% of pts, with non-significant differences in HER2- subtypes (LUM 48.5% vs. TN 39.2%, P=0.32).
Subtype* / ActMA n (%)≥10123All139 (53.5)121 (46.5)111 (42.7)25 (9.6)3 (1.2)LUM82 (48.5)87 (51.5)71 (42)9 (5.3)2 (1.2)HER2+35 (100)-22 (62.9)12 (34.3)1 (28)TN20 (39.2)31 (60.8)16 (31.4)4 (7.8)-*5 pts with unk subtype not shown
Pts with ≥2 ActMA (excluding HER2amp): 11 LUM (interestingly, 3 pts with PIK3CAmut+FGFR1amp), 1 HER2+, and 4 TN. Overall, 56% of pts received ≥1 targeted therapy (range 0-4). From the 139 pts with ≥1 potential ActMA (including HER2amp if treated with a novel anti-HER2), 61.8% received a targeted therapy and 42.4% were enrolled in a GDT: PI3K/mTOR inhibitor (inh) 54 (64.3%), novel anti-HER2 16 (19.1%), FGFR inh 8 (9.5%), AKT inh 6 (7.1%). Of the 121 pts that did not have potentially ActMA, 50% received a targeted therapy. The OR for receiving targeted therapy if ActMA was present was 1.59 (95%CI 0.94-2.70, P=0.08). Conclusion: Integration of multiplex and NGS platforms in routine molecular profiling of MBC pts yields a detection rate of ActMA >50%, which translates into higher probability of receiving a targeted agent and enrollment in a GDT. This suggests that physicians are pushing towards matched targeted therapies for pts that participate in molecular screening programs and have ActMA. Results on the outcome of these pts will be presented.
Citation Format: Oliveira M, Dienstmann R, Bellet M, Pérez-Garcia JM, Gómez P, Muñoz-Couselo E, Vidal M, Ortega V, Zamora E, Soberino J, Meire A, Nuciforo P, Vivancos A, Cortés J, Saura C. Integrating multiplex and next generation sequencing (NGS) platforms in routine molecular profiling of metastatic breast cancer (MBC) patients (pts): Trends for enrollment in genotype-directed clinical trials (GDTs). [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-08-13.
Collapse
Affiliation(s)
- M Oliveira
- Vall d'Hebron University Hospital / Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Universitat Autònoma de Barcelona, Barcelona, Spain; Oncology Data Science Group, VHIO, Barcelona, Spain; Computational Oncology Group, Sage Bionetworks, Seattle, WA; Database Managers Office, VHIO, Barcelona, Spain; Molecular Oncology Group, VHIO, Barcelona, Spain; Genomics Cancer Group, VHIO, Barcelona, Spain
| | - R Dienstmann
- Vall d'Hebron University Hospital / Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Universitat Autònoma de Barcelona, Barcelona, Spain; Oncology Data Science Group, VHIO, Barcelona, Spain; Computational Oncology Group, Sage Bionetworks, Seattle, WA; Database Managers Office, VHIO, Barcelona, Spain; Molecular Oncology Group, VHIO, Barcelona, Spain; Genomics Cancer Group, VHIO, Barcelona, Spain
| | - M Bellet
- Vall d'Hebron University Hospital / Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Universitat Autònoma de Barcelona, Barcelona, Spain; Oncology Data Science Group, VHIO, Barcelona, Spain; Computational Oncology Group, Sage Bionetworks, Seattle, WA; Database Managers Office, VHIO, Barcelona, Spain; Molecular Oncology Group, VHIO, Barcelona, Spain; Genomics Cancer Group, VHIO, Barcelona, Spain
| | - JM Pérez-Garcia
- Vall d'Hebron University Hospital / Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Universitat Autònoma de Barcelona, Barcelona, Spain; Oncology Data Science Group, VHIO, Barcelona, Spain; Computational Oncology Group, Sage Bionetworks, Seattle, WA; Database Managers Office, VHIO, Barcelona, Spain; Molecular Oncology Group, VHIO, Barcelona, Spain; Genomics Cancer Group, VHIO, Barcelona, Spain
| | - P Gómez
- Vall d'Hebron University Hospital / Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Universitat Autònoma de Barcelona, Barcelona, Spain; Oncology Data Science Group, VHIO, Barcelona, Spain; Computational Oncology Group, Sage Bionetworks, Seattle, WA; Database Managers Office, VHIO, Barcelona, Spain; Molecular Oncology Group, VHIO, Barcelona, Spain; Genomics Cancer Group, VHIO, Barcelona, Spain
| | - E Muñoz-Couselo
- Vall d'Hebron University Hospital / Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Universitat Autònoma de Barcelona, Barcelona, Spain; Oncology Data Science Group, VHIO, Barcelona, Spain; Computational Oncology Group, Sage Bionetworks, Seattle, WA; Database Managers Office, VHIO, Barcelona, Spain; Molecular Oncology Group, VHIO, Barcelona, Spain; Genomics Cancer Group, VHIO, Barcelona, Spain
| | - M Vidal
- Vall d'Hebron University Hospital / Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Universitat Autònoma de Barcelona, Barcelona, Spain; Oncology Data Science Group, VHIO, Barcelona, Spain; Computational Oncology Group, Sage Bionetworks, Seattle, WA; Database Managers Office, VHIO, Barcelona, Spain; Molecular Oncology Group, VHIO, Barcelona, Spain; Genomics Cancer Group, VHIO, Barcelona, Spain
| | - V Ortega
- Vall d'Hebron University Hospital / Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Universitat Autònoma de Barcelona, Barcelona, Spain; Oncology Data Science Group, VHIO, Barcelona, Spain; Computational Oncology Group, Sage Bionetworks, Seattle, WA; Database Managers Office, VHIO, Barcelona, Spain; Molecular Oncology Group, VHIO, Barcelona, Spain; Genomics Cancer Group, VHIO, Barcelona, Spain
| | - E Zamora
- Vall d'Hebron University Hospital / Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Universitat Autònoma de Barcelona, Barcelona, Spain; Oncology Data Science Group, VHIO, Barcelona, Spain; Computational Oncology Group, Sage Bionetworks, Seattle, WA; Database Managers Office, VHIO, Barcelona, Spain; Molecular Oncology Group, VHIO, Barcelona, Spain; Genomics Cancer Group, VHIO, Barcelona, Spain
| | - J Soberino
- Vall d'Hebron University Hospital / Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Universitat Autònoma de Barcelona, Barcelona, Spain; Oncology Data Science Group, VHIO, Barcelona, Spain; Computational Oncology Group, Sage Bionetworks, Seattle, WA; Database Managers Office, VHIO, Barcelona, Spain; Molecular Oncology Group, VHIO, Barcelona, Spain; Genomics Cancer Group, VHIO, Barcelona, Spain
| | - A Meire
- Vall d'Hebron University Hospital / Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Universitat Autònoma de Barcelona, Barcelona, Spain; Oncology Data Science Group, VHIO, Barcelona, Spain; Computational Oncology Group, Sage Bionetworks, Seattle, WA; Database Managers Office, VHIO, Barcelona, Spain; Molecular Oncology Group, VHIO, Barcelona, Spain; Genomics Cancer Group, VHIO, Barcelona, Spain
| | - P Nuciforo
- Vall d'Hebron University Hospital / Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Universitat Autònoma de Barcelona, Barcelona, Spain; Oncology Data Science Group, VHIO, Barcelona, Spain; Computational Oncology Group, Sage Bionetworks, Seattle, WA; Database Managers Office, VHIO, Barcelona, Spain; Molecular Oncology Group, VHIO, Barcelona, Spain; Genomics Cancer Group, VHIO, Barcelona, Spain
| | - A Vivancos
- Vall d'Hebron University Hospital / Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Universitat Autònoma de Barcelona, Barcelona, Spain; Oncology Data Science Group, VHIO, Barcelona, Spain; Computational Oncology Group, Sage Bionetworks, Seattle, WA; Database Managers Office, VHIO, Barcelona, Spain; Molecular Oncology Group, VHIO, Barcelona, Spain; Genomics Cancer Group, VHIO, Barcelona, Spain
| | - J Cortés
- Vall d'Hebron University Hospital / Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Universitat Autònoma de Barcelona, Barcelona, Spain; Oncology Data Science Group, VHIO, Barcelona, Spain; Computational Oncology Group, Sage Bionetworks, Seattle, WA; Database Managers Office, VHIO, Barcelona, Spain; Molecular Oncology Group, VHIO, Barcelona, Spain; Genomics Cancer Group, VHIO, Barcelona, Spain
| | - C Saura
- Vall d'Hebron University Hospital / Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Universitat Autònoma de Barcelona, Barcelona, Spain; Oncology Data Science Group, VHIO, Barcelona, Spain; Computational Oncology Group, Sage Bionetworks, Seattle, WA; Database Managers Office, VHIO, Barcelona, Spain; Molecular Oncology Group, VHIO, Barcelona, Spain; Genomics Cancer Group, VHIO, Barcelona, Spain
| |
Collapse
|
25
|
Abstract
Abstract
This paper mainly treats the thermal effects during the thermoforming process while most of the previous analyses consider an isothermal deformation. A non isothermal three dimensional finite element model of the thermoforming process is proposed. It couples the thermal equations in the thickness and mechanical equations on the mean surface of the sheet. The mechanical resolution is done by a finite element method using a membrane approximation. The deformation is driven by a pressure difference through the sheet. The thermal resolution uses a one dimension finite element method in the thickness with convection or conduction at the surface and dissipation of mechanical energy. The polymer cooling is very efficient during the contact with the tools. The coupling is done by the thermal dependent rheology. The respective contributions of friction and thermal effects in the thickness of the part during the process are discussed. The model also considers a possible multilayered material, with specific rheological parameters inside each layer. The rheology of a polystyrene was measured under elongation as a function of temperature, strain and strain-rate and described by a viscoplastic law. The predictions of the model were compared with measurements on an instrumented thermoforming machine and with the local thickness of axisymmetrical parts and with 3-D parts thermoformed with the same polystyrene.
Collapse
Affiliation(s)
- M. Bellet
- Centre de Mise en Forme des Matériaux, Ecole des Mines de Paris, Sophia Antipolis, France
| | - M.-H. Vantal
- Centre de Mise en Forme des Matériaux, Ecole des Mines de Paris, Sophia Antipolis, France
| | - B. Monasse
- Centre de Mise en Forme des Matériaux, Ecole des Mines de Paris, Sophia Antipolis, France
| |
Collapse
|
26
|
Oliveira M, Cortés J, Bellet M, Balmaña J, De Mattos-Arruda L, Gómez P, Muñoz E, Ortega V, Pérez J, Saura C, Vidal M, Rubio I, Di Cosimo S. Management of the axilla in early breast cancer patients in the genomic era. Ann Oncol 2013; 24:1163-70. [DOI: 10.1093/annonc/mds592] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open
|
27
|
Torrejon-Castro D, Zamora E, Sanchez-Olle G, Balmaña J, Gomez P, Saura C, Perez-Garcia J, Muñoz-Cousuelo E, Vidal M, Ortega V, Oliveira M, De Mattos L, Cortes J, Bellet M. Abstract P6-13-03: Symptomatic bone marrow involvement (BMinv) in breast cancer (BC): Clinical presentation, treatment and prognosis according to BC subtype and Zoledronic acid (ZA) use. A single institution review. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p6-13-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Symptomatic BMinv occurs in a minor proportion of metastatic BC patients (pts). Few data exist regarding its clinical presentation, prognosis and optimal treatment (Tx). ZA has shown to interrupt metastatic “vicious cycle” in bone and to “clear” micrometastastic BMinv in early BC, but its role in symptomatic BMinv remains unclear. We reviewed our series of pts with proven symptomatic BMinv, focusing on Tx delivered and prognosis according to BC subtype and ZA use.
Methods: Pts with histologic/cytologic evidence of BMinv from Jan2000 to Feb2012 and with any associated cytopenia were retrospectively identified from Pathology Department files.
Results: Twenty-nine pts were identified. Ductal histology: 62%, lobular 24%; Luminal (Lum = HR+/HER2−):76%; HER2+:7%, Triple negative (TN):17%. Stage: II 28%, III 34.5%, IV 24%; median (M) disease free interval: 39.6 months (m) (1.3–113.4). Time BC relapse to BMinv (M): 11.5 m (0–127). At time of BMinv onset: M age 54.7 years (34.3–77.6); M systemic Tx for metastatic disease 2 (0–7). BMinv was present at time of metastatic relapse in 11 pts, including 3 without overt bone metastasis (BM1). Other involved sites at BMinv onset: bone 90% (55% prior to BMinv), nodes 28%, liver 24% and pleuropulmonar 21%. Anemia was the most prominent hematologic sign (97%) followed by thrombocytopenia (Th) (76%) and neutropenia (35%). Tx efficacy in terms of blood count improvement (BCI) and tumor response (TR) outside BM are summarized in table 1. Most pts received non-mielotoxic regimens (endocrine therapy, weekly chemotherapy or capecitabine). ZA was administered in 22 pts (with or without overt BM1). Overall survival (OS)(M) for the whole group was 5.6m (0.3–72.9); M OS in Lum, and TN groups were 9.3 (0.4–72.9) & 0.4m (0.3–20.9+), respectively, while in the 2 HER2+ pts OS was 5.6 & 44.9+ m (p = 0.023). BC subtype, ECOG (0–1 vs 2–3), ZA use after BMinv onset and Th grade (0–1 vs ≥2) were related with OS in the univariate analysis for the whole population. ZA use after BMinv onset, Th grade and presence of BMinv at time of metastatic relapse were also significantly associated with OS in the Lum subgroup. In multivariate analysis, Th remained as an independent factor for OS both in the whole group and Lum subset. ZA use after BMinv onset showed a strong prognostic trend in the Lum group (p = 0.07).
Conclusions: BMinv has to be considered in BC pts with BM1 and otherwise unexplained cytopenia. Lum subtype correlates with 9 m M OS, while prognosis in TN subset appears to be particularly dismal. Severe th (<75000 platelets) independently predicts poor OS both in the whole population and in the Lum subtype. In this latter group, a strong trend to better outcome was seen by using ZA after BMinv diagnosis. Futher studies exploring the role of ZA use in pts with BC and symptomatic BMinv are warranted.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P6-13-03.
Collapse
Affiliation(s)
| | - E Zamora
- Vall dHebron University Hospital, Barcelona, Spain
| | | | - J Balmaña
- Vall dHebron University Hospital, Barcelona, Spain
| | - P Gomez
- Vall dHebron University Hospital, Barcelona, Spain
| | - C Saura
- Vall dHebron University Hospital, Barcelona, Spain
| | | | | | - M Vidal
- Vall dHebron University Hospital, Barcelona, Spain
| | - V Ortega
- Vall dHebron University Hospital, Barcelona, Spain
| | - M Oliveira
- Vall dHebron University Hospital, Barcelona, Spain
| | - L De Mattos
- Vall dHebron University Hospital, Barcelona, Spain
| | - J Cortes
- Vall dHebron University Hospital, Barcelona, Spain
| | - M Bellet
- Vall dHebron University Hospital, Barcelona, Spain
| |
Collapse
|
28
|
Cortes J, Calvo V, Ramírez-Merino N, O'Shaughnessy J, Brufsky A, Robert N, Vidal M, Muñoz E, Perez J, Dawood S, Saura C, Di Cosimo S, González-Martín A, Bellet M, Silva OE, Miles D, Llombart A, Baselga J. Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. Ann Oncol 2012; 23:1130-1137. [PMID: 21976387 DOI: 10.1093/annonc/mdr432] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Bevacizumab is a monoclonal antibody against vascular endothelial growth factor with the ability to increase progression-free survival in metastatic breast cancer (MBC). A systematic review and meta-analysis was conducted to determine the risk of the most clinically relevant adverse outcomes associated with the use of bevacizumab in the treatment of breast cancer. PATIENTS AND METHODS We included phase III clinical trials that used bevacizumab alone or in combination with chemotherapy as for MBC or locally recurrent. Statistical analyses were conducted to calculate summary odds ratio (OR) of the eight most relevant adverse outcomes related with bevacizumab. RESULTS Five clinical trials were included in the meta-analysis. Summary odds ratios obtained showed a statistically significant bevacizumab-associated increased risk in four of the adverse outcomes studied: proteinuria (OR = 27.68), hypertension (OR = 12.76), left ventricular dysfunction (LVD) (OR = 2.25), and hemorrhagic events (OR = 4.07). No statistically significant differences were found for gastrointestinal (GI) perforation, vascular events, fatal events, or febrile neutropenia. CONCLUSIONS Bevacizumab did increase the risk of LVD and hemorrhagic events. The addition of bevacizumab to chemotherapy in patients with metastatic breast cancer was not associated with a significant increase in grade ≥ 3 arterial or venous thromboembolic events, GI perforation, or fatal events.
Collapse
Affiliation(s)
- J Cortes
- Department of Medical Oncology, Vall d´Hebron University Hospital, Barcelona.
| | - V Calvo
- Department of Medical Oncology, Ramón y Cajal University Hospital, Madrid
| | - N Ramírez-Merino
- Department of Medical Oncology, Hospital Universitario de Guadalajara, Guadalajara, Spain
| | - J O'Shaughnessy
- Department of Medical Oncology, Baylor-Charles A. Sammons Cancer Center, Texas Oncology, and US Oncology, Dallas
| | - A Brufsky
- Department of Medical Oncology, University of Pittsburgh Medical Center, Pittsburgh
| | - N Robert
- Department of Medical Oncology, Virginia Cancer Specialists, US Oncology, Fairfax, USA
| | - M Vidal
- Department of Medical Oncology, Vall d´Hebron University Hospital, Barcelona
| | - E Muñoz
- Department of Medical Oncology, Vall d´Hebron University Hospital, Barcelona
| | - J Perez
- Department of Medical Oncology, Vall d´Hebron University Hospital, Barcelona
| | - S Dawood
- Department of Medical Oncology, Dubai Hospital, Dubai Health Authority, Dubai, United Arab Emirates
| | - C Saura
- Department of Medical Oncology, Vall d´Hebron University Hospital, Barcelona
| | - S Di Cosimo
- Department of Medical Oncology, Vall d´Hebron University Hospital, Barcelona
| | - A González-Martín
- Department of Medical Oncology, MD Anderson Cancer Center, Madrid, Spain
| | - M Bellet
- Department of Medical Oncology, Vall d´Hebron University Hospital, Barcelona
| | - O E Silva
- Department of Medical Oncology, University of Miami Leonard M. Miller School of Medicine, Miami, USA
| | - D Miles
- Department of Medical Oncology, Mount Vernon Cancer Centre, Middlesex, UK
| | - A Llombart
- Department of Medical Oncology, Arnau de Vilanova Hospital, Lérida, Spain
| | - J Baselga
- Department of Medical Oncology, Massachusetts General Hospital, Boston, USA
| |
Collapse
|
29
|
Vidal M, Di Cosimo S, Torrejon D, Saura C, Gómez-Pardo P, Pérez-Garcia J, Muñoz-Couselo E, Bellet M, Sanchez-Olle G, De MAL, Oliveira M, Tabernero J, Baselga J, Cortes J. P5-13-01: Survival Outcome with Bevacizumab: Activation of the Phosphatidylinositol-3 Kinase (PI3K) Pathway Due to PIK3CA Mutations or PTEN Loss Makes a Difference. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p5-13-01] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
The PI3K pathway is known to regulate the transcription of Vascular Endothelial Growth Factor (VEGF) in endothelial and cancer cells. The inhibition of VEGF is the rationale behind the development therapy with anti-angiogenics. We investigated the activation of PI3K pathway, defined as PTEN loss and/or PIK3CA mutations, and the relationship with survival in metastatic breast cancer patients treated with the anti-VEGF monoclonal antibody bevacizumab.
Patients and methods: Records for patients with HER2 negative metastatic breast cancer (MBC), treated with bevacizumab from July 2005 to June 2010, and with known PI3K status were reviewed. Univariate and multivariate analysis were performed using SPSS 15.0.
Results: A total of 40 patients — 26 with and 14 without PI3K activation — were identified. Median age was 47 years (range 27–79). Median overall survival (OS) was 41.23 months (CI 95%: 27.29 — 55.18) and 66.23 months (CI 95%: 61.04 — 71.42) in patients with and without PI3K activation, respectively (p=0.04). Among patients with PI3K activation, OS was 34.13 months (CI 95%: 22.40 — 45.86) and 43.43 months (CI 95%: 26.9 — 59.97) in cases with PIK3CA mutations and PTEN loss, respectively. As compared to patients without PI3K activation, patients with PI3KCA mutations but not patients with PTEN loss showed a significant worse outcome (p=0.006 and p=0.3, respectively). In the multivariate analysis including grade, hormone receptor and Ki67 status, and total lines of treatment, the activation of PI3K activation proved to be an independent prognostic factor (p=0.03).
Conclusions: The activation of the PI3K pathway is significantly associated with decreased OS of MBC patients treated with bevacizumab. Prospective evaluation of PI3K activation on VEGF signaling with differential implication of PI3KCA and PTEN loss is warranted.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P5-13-01.
Collapse
Affiliation(s)
- M Vidal
- 1Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; Massachusetts General Hospital Cancer Center. Harvard Medical School, Boston
| | - S Di Cosimo
- 1Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; Massachusetts General Hospital Cancer Center. Harvard Medical School, Boston
| | - D Torrejon
- 1Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; Massachusetts General Hospital Cancer Center. Harvard Medical School, Boston
| | - C Saura
- 1Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; Massachusetts General Hospital Cancer Center. Harvard Medical School, Boston
| | - P Gómez-Pardo
- 1Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; Massachusetts General Hospital Cancer Center. Harvard Medical School, Boston
| | - J Pérez-Garcia
- 1Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; Massachusetts General Hospital Cancer Center. Harvard Medical School, Boston
| | - E Muñoz-Couselo
- 1Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; Massachusetts General Hospital Cancer Center. Harvard Medical School, Boston
| | - M Bellet
- 1Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; Massachusetts General Hospital Cancer Center. Harvard Medical School, Boston
| | - G Sanchez-Olle
- 1Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; Massachusetts General Hospital Cancer Center. Harvard Medical School, Boston
| | - Mattos-Arruda L De
- 1Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; Massachusetts General Hospital Cancer Center. Harvard Medical School, Boston
| | - M Oliveira
- 1Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; Massachusetts General Hospital Cancer Center. Harvard Medical School, Boston
| | - J Tabernero
- 1Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; Massachusetts General Hospital Cancer Center. Harvard Medical School, Boston
| | - J Baselga
- 1Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; Massachusetts General Hospital Cancer Center. Harvard Medical School, Boston
| | - J Cortes
- 1Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; Massachusetts General Hospital Cancer Center. Harvard Medical School, Boston
| |
Collapse
|
30
|
Castro DT, Di Cosimo S, Vidal M, Gomez P, Bellet M, Saura C, Perez-Garcia J, Mufioz E, Baselga J, Cortes J. 5064 POSTER Breast Cancer Subtype and Survival in Metastatic Patients Treated With Bevacizumab. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71506-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
31
|
De Mattos-Arruda L, Oliveira M, Sánchez-Ollé G, Moreno-Fernandez D, Graña B, Cortes J, Bellet M, Di Cosimo S, Gomez Pardo P, Rodon Ahnert J, Perez-Garcia JM, Vidal M, Muñoz-Couselo E, Hernandez-Losa J, Vivancos A, Prudkin L, Aura C, Baselga J, Tabernero J, Saura C. Evaluation of overall survival (OS) in patients (pts) with metastatic breast cancer (MBC) according to phosphathidylinositol-3-kinase (PI3K) pathway status. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e21130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
32
|
Oliveira M, De Mattos-Arruda L, Sánchez-Ollé G, Graña B, Cortes J, Perez-Garcia JM, Muñoz-Consuelo E, Vidal M, Bellet M, Di Cosimo S, Gomez Pardo P, Rodon Ahnert J, Hernandez-Losa J, Vivancos A, Prudkin L, Aura C, Serra V, Baselga J, Tabernero J, Saura C. Prognostic implications of phosphatidylinositol 3-kinase (PI3K) pathway alterations in metastatic triple-negative breast cancer (mTNBC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.1081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
33
|
Moy B, Lebrun F, Bellet M, Chow L, Lang I, Xu B, Badwe RA, Hershman DL, Leip E, Bardy-Bouxin N, Duvillie L, Neven P. Bosutinib and exemestane (EXE) versus EXE alone in postmenopausal (postm) women with hormone receptor–positive (HR+) HER2-negative (HER2–) advanced breast cancer (ABC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
34
|
Vidal M, Perez-Garcia JM, Muñoz E, Saura C, de Mattos L, Gomez P, Cortes J, Baselga J, Bellet M. Abstract P2-09-27: Predictive Factors of Complete Axillary Downstaging after Neoadjuvant Chemotherapy in Breast Cancer Patients. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p2-09-27] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The axillary status after neoadjuvant chemotherapy (NACT) is an important prognostic factor. Complete axillary downstaging (CAD) occurs in up to 20-30% of the patients, however, sentinel node biopsy after NACT is not recommended in patients with initial axillary nodal involvement and complete axillary response after NACT. Our aim was to investigate predictive factors of CAD after NACT to identify patients who could avoid an unnecessary axillary dissection. Patients and methods: From January 2004 to December 2008, 256 consecutive patients were diagnosed with invasive breast cancer and received NACT and breast surgery at our institution. Patients were eligible for this analysis if they met the following inclusion criteria: clinically and/or cytologically proven metastatic axillary nodes; complete axillary response after NACT; and complete axillary dissection after systemic treatment. CAD was defined as pN0 (isolated tumor cells and micrometastasis were excluded). Univariate and multivariate analyses were performed to assess the association between CAD and either tumor characteristics or intrinsic cancer subtypes.
Results: 84 patients were included. Median age was 51.64 years. 75 (89,3%) received anthracyclines-and taxanes-based CT and 11 (13%). 38 (45,2%) had cytologically proven metastatic axillary nodes at diagnosis. According to intrinsic cancer subtypes, 22 (26%) were classified as HER2 positive, 17 (20,2%) as triple negative (ER, PR, and HER2 -), 6 (7,1%) as luminal A [estrogen receptor positive and/or progesterone receptor positive and (Ki67 < 20% and histological grade 1 or 2)], and 23 (27,4%) as luminal B [estrogen receptor positive and/or progesterone receptor positive and (Ki67 ≥20% or histological grade 3)]. In the univariate analysis, HER2 positivity (p=0,002) and neoadjuvant treatment with trastuzumab (p=0,019) were significantly associated with CAD. In the multivariate analysis only HER2 status maintained statistical significance (p=0,003). Among luminal A, luminal B, and triple negative tumors, complete axillary response after NACT did not significantly predict CAD.
Conclusions: In our cohort of breast cancer patients, HER2 status is an independent predictive factor of CAD after NACT. Clinical trials, probably according to specific breast cancer subtypes, are required to identify patients with initial axillary metastatic involvement who could avoid an axillary dissection after systemic therapy.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P2-09-27.
Collapse
Affiliation(s)
- M Vidal
- Vall d'Hebron University Hospital, Barcelona, Spain
| | | | - E Muñoz
- Vall d'Hebron University Hospital, Barcelona, Spain
| | - C Saura
- Vall d'Hebron University Hospital, Barcelona, Spain
| | - L de Mattos
- Vall d'Hebron University Hospital, Barcelona, Spain
| | - P Gomez
- Vall d'Hebron University Hospital, Barcelona, Spain
| | - J Cortes
- Vall d'Hebron University Hospital, Barcelona, Spain
| | - J Baselga
- Vall d'Hebron University Hospital, Barcelona, Spain
| | - M. Bellet
- Vall d'Hebron University Hospital, Barcelona, Spain
| |
Collapse
|
35
|
Perez-Garcia JM, Saura C, Muñoz E, Moreno-Fernandez D, Gomez P, Vidal M, Di Cosimo S, Cortes J, Baselga J, Bellet M. Role of progesterone receptor status (PR) as predictive factor of pathologic complete response (pCR) to neoadjuvant chemotherapy (NACT) in breast cancer patients. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.628] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
36
|
Ramirez Merino N, Calvo V, Vidal M, Bellet M, Perez J, Llombart-Cussac A, Cortes-Funes H, Miles D, Baselga J, Cortes J. Risk of gastrointestinal perforation in patients with metastatic breast cancer treated with bevacizumab: A meta-analysis. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.1091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
37
|
Freixinós V, Sánchez-Ollé G, De Mattos-Arruda L, Di Cosimo S, Saura C, Gomez P, Perez-Garcia JM, Cortes J, Baselga J, Bellet M. Efficacy of vinorelbine plus trastuzumab (VT) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab (T). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.1113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
38
|
Muñoz E, Perez-Garcia JM, Saura C, Vidal M, Sanchez-Olle G, Bellet M, Gomez P, Di Cosimo S, Baselga J, Cortes J. Low cardiotoxicity of nonpegylated liposomal doxorubicin (NPLD) in patients (pts) with metastatic breast cancer (MBC) previously exposed to 360 mg/m 2 of doxorubicin (D). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.1112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
39
|
Pradille C, Bellet M, Chastel Y. A complete method for rheological characterization of steel at high temperature. EPJ Web of Conferences 2010. [DOI: 10.1051/epjconf/20100617001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
40
|
Serrano C, Cortés J, Russillo M, Bellet M, Gómez P, Saura C, Pérez J, Farriols A, Baselga J, Cosimo SD. 4012 Adjuvant docetaxel and cyclofosfamide in breast cancer patients over 65 years: compliance and toxicity. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)70746-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
41
|
Serrano C, Cortés J, Russillo M, Bellet M, Gómez P, Saura C, Pérez J, Carreras M, Baselga J, Cosimo SD. 4005 Trastuzumab-related cardiotoxicity in the elderly: which role for cardiovascular risk factors? EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)70739-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
42
|
Perez Garcia JM, Saura C, Muñoz E, Sanchez-Olle G, Gomez P, Peg V, Sabadell D, Cortes J, Baselga J, Bellet M. Role of progesterone receptor status (PR) as predictive factor of pathological complete response (pCR) to neoadjuvant chemotherapy (NACT) in breast cancer (BC) patients (pts). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.637] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
637 Background: While estrogen receptor (ER) negativity has been consistently associated to higher pCR rates after NACT in BC, few data regarding the association of PR with pCR has been reported. PR positivity has been related to taxol resistance in in vitro chemosensitivity assays. Our aim was to investigate the putative role of PR in the prediction of pCR in a cohort of BC pts receiving NACT. Methods: Medical reports of all pts receiving NACT and breast surgery between 2004 and 2006 in our institution were reviewed. Baseline clinical and histological features, along with type of preoperative therapy were examined as variables for association with pCR (no invasive tumor in breast and axilla) using univariate and multivariate analyses. Results: 128 pts were included. 73.4% received anthracycline and taxanes (A&Tx) based CT and 9.4% also received trastuzumab (T). PR+ (≥ 10%) was significantly associated with low histological grade (HG), low Ki67 (<10%), HER-2- (Herceptest 0,1,or 2 with FISH-) and ER+ (≥10%). Overall pCR rate was 18.8%. No PR+ patient achieved pCR. In univariate analysis, high HG, ER-, PR-, HER-2-, high Ki67, T therapy, and number of CT cycles were significantly associated with pCR. In multivariate analysis only HER-2 and PR status were statistically significant. Similarly, PR and HER-2 status were independently related to pCR in the subgroup of pts receiving A&Tx (N = 94, 20.2%pCR). In the HER-2- subgroup (n = 89, 9%pCR) only ER independently predicted pCR, while in the HER-2+ subgroup (n = 33, 42.4%pCR, 57.1%pCR with T), both PR- and T therapy were the only predictive factors for pCR in the univariate and multivariate analyses. When the 24 HER-2+ pts treated with A&Tx (23 taxol/1 taxotere) ± T were separately analyzed, only PR retained statistical significance in the multivariate model. Conclusions: In our cohort of BC pts treated with NACT, PR status independently predicts pCR in the whole population as well as in the A&Tx-treated and in the HER-2+ subgroups. In the HER-2+ pts receiving A&Tx ± T PR negativity was the only factor associated with pCR. PR status merits further investigation as a predictive factor for pCR to NACT, in particular in HER-2+ population. No significant financial relationships to disclose.
Collapse
Affiliation(s)
| | - C. Saura
- Breast Cancer Centre, Vall d'Hebron Hospital, Barcelona, Spain
| | - E. Muñoz
- Breast Cancer Centre, Vall d'Hebron Hospital, Barcelona, Spain
| | - G. Sanchez-Olle
- Breast Cancer Centre, Vall d'Hebron Hospital, Barcelona, Spain
| | - P. Gomez
- Breast Cancer Centre, Vall d'Hebron Hospital, Barcelona, Spain
| | - V. Peg
- Breast Cancer Centre, Vall d'Hebron Hospital, Barcelona, Spain
| | - D. Sabadell
- Breast Cancer Centre, Vall d'Hebron Hospital, Barcelona, Spain
| | - J. Cortes
- Breast Cancer Centre, Vall d'Hebron Hospital, Barcelona, Spain
| | - J. Baselga
- Breast Cancer Centre, Vall d'Hebron Hospital, Barcelona, Spain
| | - M. Bellet
- Breast Cancer Centre, Vall d'Hebron Hospital, Barcelona, Spain
| |
Collapse
|
43
|
Serrano C, Cortés J, Bellet M, Gómez P, Saura C, Martínez P, Pérez J, Atzori F, Baselga J, Di Cosimo S. Trastuzumab in the elderly: Is it age or cardiovascular risk profile that really matters? J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e20527] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e20527 Background: Elderly breast cancer (BC) patients (pts) are usually excluded from clinical trials. Nevertheless, with the increased use of trastuzumab (T) there is a need to assess and predict T-related cardiotoxicity in this population. Methods: Data were collected from women ≥70 years with BC and serial cardiac monitoring treated with T at our institution since 2005. Cardiovascular risk factors (CRF) were analysed together with left ventricular systolic function (LVEF) assessed at baseline and during T. Results: Thirty pts with early (10) or advanced (20) BC, median age 75.7 years (range 70–87), were identified. WHO performance status was 0–1 in 90% of pts. Median duration of treatment was 45 weeks (range 2–87). Basal LVEF was 63.8% (range 46.3–76). Five of 30 pts (16.6%) experienced asymptomatic cardiotoxicity defined as an absolute drop ≥10% with a final LVEF < 50% (13.3%, 4/30 pts) or any absolute drop >20% (3.3%, 1/30 pts). Four of 30 patients (13.3%) developed symptomatic cardiac heart failure. Median time to LVEF decline was 9 weeks (range 3–87). LVEF recovered to normal values in a median time of 4 weeks (range 3–48) in all but one patient. CRF are shown in Table 1 . Pts with T-related cardiotoxicity presented more often with history of cardiac disease (22.2% versus 9.5%), diabetes (22.2% versus 5%) and BMI>30 (68% versus 45%) as compared to the rest. No relevant difference was seen in terms of hyperlipemia, tobacco or hypertension. Previous or concomitant exposure to anthracyclines was not found as a risk factor either. Conclusions: Despite the limited numbers, this series shows that elderly BC pts treated with T experience reversible cardiac events similarly to those already described in younger pts. However, particular attention may be paid to cardiac history, diabetic and obese pts who appear more likely to develop T-related cardiotoxicity. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- C. Serrano
- Breast Cancer Centre, Vall d'Hebron Hospital, Barcelona, Spain
| | - J. Cortés
- Breast Cancer Centre, Vall d'Hebron Hospital, Barcelona, Spain
| | - M. Bellet
- Breast Cancer Centre, Vall d'Hebron Hospital, Barcelona, Spain
| | - P. Gómez
- Breast Cancer Centre, Vall d'Hebron Hospital, Barcelona, Spain
| | - C. Saura
- Breast Cancer Centre, Vall d'Hebron Hospital, Barcelona, Spain
| | - P. Martínez
- Breast Cancer Centre, Vall d'Hebron Hospital, Barcelona, Spain
| | - J. Pérez
- Breast Cancer Centre, Vall d'Hebron Hospital, Barcelona, Spain
| | - F. Atzori
- Breast Cancer Centre, Vall d'Hebron Hospital, Barcelona, Spain
| | - J. Baselga
- Breast Cancer Centre, Vall d'Hebron Hospital, Barcelona, Spain
| | - S. Di Cosimo
- Breast Cancer Centre, Vall d'Hebron Hospital, Barcelona, Spain
| |
Collapse
|
44
|
Counil FP, Karila C, Le Bourgeois M, Matecki S, Lebras MN, Couderc L, Fajac I, Reynaud-Gaubert M, Bellet M, Gauthier R, Denjean A. Mucoviscidose : du bon usage des explorations fonctionnelles respiratoires. Rev Mal Respir 2007; 24:691-701. [PMID: 17632430 DOI: 10.1016/s0761-8425(07)91145-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
INTRODUCTION Neonatal screening for cystic fibrosis (CF) leads to early dedicated specialist care for all patients. BACKGROUND Pulmonary function tests (PFT) are mandatory for routine monitoring of CF patients. The aim of this article is to review the current guidelines for PFTs in CF, particularly the type of test, the age and the clinical status of the patient. VIEWPOINT The regular use of spirometry is generally accepted. Many other tests are used but their clinical value in the routine follow-up of CF patients remains to be established. CONCLUSION Further efforts should be made to evaluate the value of PFTs in CF, particularly in very young children.
Collapse
Affiliation(s)
- F P Counil
- CHU Arnaud de Villeneuve, Montpellier, France.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Mihaylova Z, Ludovini V, Gregorg V, Floriani I, Pistola L, Toffaneti F, Ferraldeschi M, Spreafico A, Ceresoli GL, Bellet M, Darwish S, Tonato M, Raynov J. Serum level changes of matrix metalloproteinases 2 and 9, vascular endothelial growth factor and epidermal growth factor receptor during platinum-based chemotherapy in advanced non-small cell lung cancer patients. J BUON 2007; 12:105-11. [PMID: 17436410] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/14/2023]
Abstract
PURPOSE To evaluate serum changes of matrix metalloproteinases (MMPs) 2 and 9, vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) levels in patients with advanced non-small cell lung cancer (NSCLC) and their association with main clinicopathological parameters during chemotherapy with cisplatin and gemcitabine. PATIENTS AND METHODS In this prospective study, consecutive patients with stage III and IV NSCLC were enrolled. Serum MMP2 and 9, VEGF and EGFR levels were monitored in blood samples taken on day 1 of starting chemotherapy (baseline 1st), and after 3 cycles of chemotherapy (2nd) using commercial sandwich ELISA method. RESULTS 116 patients were evaluated. Males / females 100 / 6, ECOG performance status (PS) 0/1/2: 47/65/4, stage III / IV: 49/67, squamous /adeno/large cell carcinoma 41/31/19. Forty-two (36%) patients achieved partial response (PR), 32 (28%) stable disease (SD) and 42 (36%) showed progressive disease (PD). Mean serum values -/+ standard deviation (SD) of the analyzed markers at baseline/at response evaluation were: EGFR 86 -/+ 87/96 -/+ 47 fmol/ml; MMP9 236 -/+ 156/162 -/+ 133 ng/ml ; MMP2 525 -/+ 189/569 -/+ 201 ng/ml; VEGF 555 -/+ 476/599 -/+ 611 pg/ml; VEGF adjusted for platelets (PLT) 1.9 -/+ 1.45/2.4 -/+ 2.78 pg/10(6). In logistic regression model for response rate adjusted for stage, the increase in MMP9 levels during chemotherapy (mean = 74 ng/ml -/+ SD 140) was predictive for progression (p=0.041) with 5% increase in the odds of progression for an increase of 10 ng. CONCLUSION MMP9 level increase was found to be predictive of disease progression. EGFR levels could refl ect extracellular domain (ECD) loss from resistant cells and its shedding into the circulation.
Collapse
Affiliation(s)
- Zh Mihaylova
- Department of Hematology and Oncology, Military Medical Academy, Sofia, Bulgaria.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Gomez P, Vilar E, Saura C, Cortes J, Ocaña A, Bellet M, Carrera J, Baselga J. Feasibility of pegfilgrastim as haematopoietic support for dose-dense every-2-week adjuvant chemotherapy in breast cancer. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.18606] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
18606 Background: Dose-dense sequential chemotherapy has been safety supported with Filgrastim (F). Pegfilgrastim (PEGF) is a pegylated recombinant human granulocyte colony-stimulating factor (G-CSF) that has a long half-life, a fact that facilitates a less frequent dosing. Its safety and efficacy has been established in 21- and 28-days schedules. Methods: We have performed a retrospective analysis of medical records of 2 cohort of patients (n=38) treated at our institution between December 2003 and November 2005. All patients received Adriamicin 60 mg/m2 plus Ciclophosphamide 600 mg/m2 q2w for 4 cycles followed by Paclitaxel 175 mg/m2 q2w for 4 cycles. As G-CSF support, in Cohort A (n=29) PEGF was administered 6 mg on day 2 of each cycle and in Cohort B (n=9) F days 3 to 10 at 5 μg/kg. The primary end point was to explore the feasibility and safety in terms of febrile neutropenia (FN) events, number of treatment delays (TD), incidence of neutropenia grade 3 (NPG3) and 4 (NPG4) and mean absolute neutrophil count (ANC) on day 14 of cycle 1 to 7 for both groups. Indirect comparisons have been performed. Results: Patients characteristics in both cohorts were well balanced, except for age in cohort A compared with cohort B (44,89 versus 52,5, p = 0,02). FN events and TD were increased in cohort B compared with cohort A (22% versus 0%, p=0.051, both comparisons). No statistically significant difference in number of episodes of NPG3 and NPG4 was observed. Median ANC on day 14 for each treatment cycle was significantly greater for Cohort A than Cohort B, except for cycle 6. Conclusions: PEGF is very safe and efficacy in patients treated with dose-dense sequential adjuvant chemotherapy for breast cancer. It could be even more efficient than F in preventing febrile neutropenia events. [Table: see text]
Collapse
Affiliation(s)
- P. Gomez
- Vall d’Hebron University Hospital, Barcelona, Spain
| | - E. Vilar
- Vall d’Hebron University Hospital, Barcelona, Spain
| | - C. Saura
- Vall d’Hebron University Hospital, Barcelona, Spain
| | - J. Cortes
- Vall d’Hebron University Hospital, Barcelona, Spain
| | - A. Ocaña
- Vall d’Hebron University Hospital, Barcelona, Spain
| | - M. Bellet
- Vall d’Hebron University Hospital, Barcelona, Spain
| | - J. Carrera
- Vall d’Hebron University Hospital, Barcelona, Spain
| | - J. Baselga
- Vall d’Hebron University Hospital, Barcelona, Spain
| |
Collapse
|
47
|
Saura C, Vilar E, Cortes J, Bellet M, Ocaña A, Gomez P, Baselga J. Pegfilgrastim induces elevation of serum CA 15–3 in breast carcinoma patients after receiving dose-dense adjuvant chemotherapy. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.8595] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8595 Background: CA 15–3, an epytope related with MUC-1 gene products, is a well known tumour marker to predict early recurrent disease breast cancer. MUC-1 expression can be detected in neutrophil membrane and cytoplasm. It is known that patients with breast cancer who receive adjuvant chemotherapy with G-CSF support may show CA 15–3 false positive elevations Methods: We identified by medical records 76 patients who received adjuvant sequential chemotherapy for breast cancer consisted in Doxorubicin/Ciclophosphamide for 4 cycles followed by Paclitaxel for 4 cycles every-2 (with haematopoietic support with Pegfilgrastim (Cohort A, n=29) or Filgrastim (Cohort B, n=10)) and every-3-weeks without haematopoietic support (cohort C, n=37) between October 2003 and November 2005. Mean values of CA 15–3 recorded at the first follow up (FU) visit after treatment and number of patients with levels above the cut-off value of 40 U/mL were compared between the three patients cohorts. Correlation between CA 15–3 with alkaline phosphatase (AP) levels measured at first FU and with absolute neutrophil count (ANC) mean values measured on day 14 of every cycle were performed for each cohort Results: Patients characteristics between cohorts were well balanced except for age. A statistically significantly difference in median CA 15–3 post-treatment values were observed between Cohort A and C (34.01 versus 22.3, p=0.001), but no between Cohort A and B (34.01 versus 30.53). Eight patients in Cohort A, 2 in B and 1 in C had CA 15–3 levels above 40 UI/mL (27.6% versus 20% versus 2.7%, p=0.009). CA 15–3 decreased to normal values at subsequent visits. CA 15–3, mean ANC (r= 0.272, p= 0.020), and AP (r= 0.361, p= 0.002) were found associated each other when the whole database was analyzed Conclusions: These data provide evidence that Pegfilgrastim induces elevation of CA 15–3 level in comparison with patients treated without G-CSF support. This elevation may be related to the increased neutrophil counts. Physicians should be aware of this fact during the follow up to avoid unnecessary diagnostic workup. [Table: see text]
Collapse
Affiliation(s)
- C. Saura
- Vall d’Hebron University Hospital, Barcelona, Spain
| | - E. Vilar
- Vall d’Hebron University Hospital, Barcelona, Spain
| | - J. Cortes
- Vall d’Hebron University Hospital, Barcelona, Spain
| | - M. Bellet
- Vall d’Hebron University Hospital, Barcelona, Spain
| | - A. Ocaña
- Vall d’Hebron University Hospital, Barcelona, Spain
| | - P. Gomez
- Vall d’Hebron University Hospital, Barcelona, Spain
| | - J. Baselga
- Vall d’Hebron University Hospital, Barcelona, Spain
| |
Collapse
|
48
|
Bellet M, Muñoz M, Bellosillo B, Corominas J, Pena T, Suárez M, Maristany M, Perich J, Tusquets I, Fabregat X. Phase II study of capecitabine (X) + docetaxel (T) as neoadjuvant treatment in patients (pts) with locally advanced breast cancer (LABC) including biological correlates. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.664] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
664 Background: X and T have demonstrated synergy in preclinical studies and survival benefits in metastatic BC. We aimed to determine whether the high efficacy of XT could translate into the neoadjuvant setting. Methods: Expression levels (mRNA) of 3 enzymes involved in X intratumoral activation and metabolism (thymidylate synthase [TS], thymidine phosphorylase [TP] and dihydropyrimidine dehydrogenase [DPD]), were determined in tumor biopsies before treatment and their relationship with clinical and pathological response analyzed using Fisher’s Exact Test. Pts with stage IIIA/IIIB LABC, adequate organ function and KPS ≥80 received 4 cycles of X 1250mg/m2 (1000mg/m2 for age >60) bid d1–14 and T 75mg/m2 d1 q3w followed by surgery, adjuvant AC q3w × 4 ± tamoxifen according to ER and PR status. The primary endpoint was pCR. Results: We enrolled 34 pts with LABC IIIA (44%)/IIIB (56%): median age 52y (30–72); KPS ≥90 (76%); median tumor size 6.8cm (2–20); N0 (20%), N1 (41%), N2/3 (35%); ER+PR-/p53+/HER2+ (23/24/28%). 128 cycles of X and T were administered (median 4, range 1–5). Main G3/G4 toxicities were: HFS 32%, diarrhea 15%, asthenia 9%, stomatitis 6% and neutropenia 71%. There were no treatment-related deaths. 2 pts were withdrawn prematurely due to adverse events. The overall response in 32 evaluable pts was 78%, including 5 CRs and 20 PRs. 6/29 pts evaluable for pathological response had pCR (20%), and 10 (33%) had ≤10mm residual tumor (3 microscopic RD) in breast. Nodal involvement after chemotherapy was N0 (33%), N1 (33%), N2 (27%), N3 (7%), and the rate of breast-conserving surgery was 17%. High TP/DPD ratio was associated with CR (p=0.037) and both high TP/DPD and low TS/DPD ratio appeared to correlate with residual tumor ≤10 mm (p=0.028). Conclusions: Neoadjuvant XT appears to be highly active. Safety was similar to that reported in anthracycline-pretreated pts but with less stomatitis. In this small sample, a high TP/DPD ratio appears to correlate with clinical response and a favorable enzymatic profile (high TP/DPD and low TS/DPD ratio) may predict for high pCR. A further prospective study is required to validate this hypothesis. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. Bellet
- Hospital del Mar, Barcelona, Spain; Hospital Clinic, Barcelona, Spain; Roche Farma, Madrid, Spain
| | - M. Muñoz
- Hospital del Mar, Barcelona, Spain; Hospital Clinic, Barcelona, Spain; Roche Farma, Madrid, Spain
| | - B. Bellosillo
- Hospital del Mar, Barcelona, Spain; Hospital Clinic, Barcelona, Spain; Roche Farma, Madrid, Spain
| | - J. Corominas
- Hospital del Mar, Barcelona, Spain; Hospital Clinic, Barcelona, Spain; Roche Farma, Madrid, Spain
| | - T. Pena
- Hospital del Mar, Barcelona, Spain; Hospital Clinic, Barcelona, Spain; Roche Farma, Madrid, Spain
| | - M. Suárez
- Hospital del Mar, Barcelona, Spain; Hospital Clinic, Barcelona, Spain; Roche Farma, Madrid, Spain
| | - M. Maristany
- Hospital del Mar, Barcelona, Spain; Hospital Clinic, Barcelona, Spain; Roche Farma, Madrid, Spain
| | - J. Perich
- Hospital del Mar, Barcelona, Spain; Hospital Clinic, Barcelona, Spain; Roche Farma, Madrid, Spain
| | - I. Tusquets
- Hospital del Mar, Barcelona, Spain; Hospital Clinic, Barcelona, Spain; Roche Farma, Madrid, Spain
| | - X. Fabregat
- Hospital del Mar, Barcelona, Spain; Hospital Clinic, Barcelona, Spain; Roche Farma, Madrid, Spain
| |
Collapse
|
49
|
Forey P, Giroux-Metges MA, Sarni D, Goetghebeur D, Thirion S, Milic-Emili J, Bellet M. [Evaluation of a new method for detection of obstructive disease in children asthma: the negative expiratory pressure (NEP)]. Arch Pediatr 2005; 12:1338-43. [PMID: 16023842 DOI: 10.1016/j.arcped.2005.05.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2004] [Accepted: 05/21/2005] [Indexed: 11/19/2022]
Abstract
INTRODUCTION To take in charge of an asthmatic child it is necessary to evaluate the lung function. METHODS In this study, the Negative Expiratory Pressure (NEP) has been used for the first time in children with asthma. After lung spirometry by plethysmography, we have used the NEP to assess the prevalence of expiratory flow limitation (FL) during resting breath in 27 asthmatic children (mean age: 11 +/- 2,5 years) 3-4 days after a crisis in both sitting and supine positions. RESULTS All the children presented an obstructive defect (FEV 1: 63 +/- 13% med) and a dynamic hyperinflation (FRC: 128 +/- 25% med). According to the NEP, 11 children presented an expiratory flow limitation (FL). Asthma was more severe in the FL than in non-FL children (GINA 2002 classification). Among the 11 FL children, 5 were FL in both sitting and supine position and 6 only in supine. Nine of the 27 children were FL with the conventional method. NEP seems a more accurate method to assess the clinical gravity of asthma than FEV 1. The reduction of FRC in the supine position probably explains the greater incidence of FL in supine position. CONCLUSION Because of its easy execution, NEP seems to be well adapted for children. Links between FL detected by NEP and clinical signs of asthma has to be assessed by furthers studies including more patients.
Collapse
Affiliation(s)
- P Forey
- Service de pédiatrie, CHU Morvan, 29609 Brest cedex, France
| | | | | | | | | | | | | |
Collapse
|
50
|
Bellet M, Muñoz M, Suárez M, Corominas J, Bellosillo B, Maristany T, Perich J, Tusquets I, Fabregat X. Phase II study of capecitabine (C) in combination with docetaxel (D) as neoadjuvant treatment in patients with locally advanced breast cancer (IIIA and IIIB stage). Correlation between clinico-pathological response and fluoropyrimidine-enzyme profile. Early results. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.735] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. Bellet
- Hosp del Mar, Barcelona, Spain; Oncology Dept, Hosp Clínic, Barcelona, Spain
| | - M. Muñoz
- Hosp del Mar, Barcelona, Spain; Oncology Dept, Hosp Clínic, Barcelona, Spain
| | - M. Suárez
- Hosp del Mar, Barcelona, Spain; Oncology Dept, Hosp Clínic, Barcelona, Spain
| | - J. Corominas
- Hosp del Mar, Barcelona, Spain; Oncology Dept, Hosp Clínic, Barcelona, Spain
| | - B. Bellosillo
- Hosp del Mar, Barcelona, Spain; Oncology Dept, Hosp Clínic, Barcelona, Spain
| | - T. Maristany
- Hosp del Mar, Barcelona, Spain; Oncology Dept, Hosp Clínic, Barcelona, Spain
| | - J. Perich
- Hosp del Mar, Barcelona, Spain; Oncology Dept, Hosp Clínic, Barcelona, Spain
| | - I. Tusquets
- Hosp del Mar, Barcelona, Spain; Oncology Dept, Hosp Clínic, Barcelona, Spain
| | - X. Fabregat
- Hosp del Mar, Barcelona, Spain; Oncology Dept, Hosp Clínic, Barcelona, Spain
| |
Collapse
|